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ABSTRACT OF DISSERTATION

REGULATION OF PANCREATIC β-CELL FUNCTION BY THE
RENIN-ANGIOTENSIN SYSTEM IN TYPE 2 DIABETES
Diet-induced obesity promotes type 2 diabetes (T2D). Drugs that inhibit the
renin-angiotensin system (RAS) have been demonstrated in clinical trials to
decrease the onset of T2D. Previously, we demonstrated that mice made obese
from chronic consumption of a high-fat (HF) diet have marked elevations in
systemic concentrations of angiotensin II (AngII). Pancreatic islets have been
reported to possess components of the renin-angiotensin system (RAS),
including angiotensin type 1a receptors (AT1aR), the primary receptor for AngII,
and angiotensin converting-enzyme 2 (ACE2), which negatively regulates the
RAS by catabolizing AngII to angiotensin-(1-7) (Ang-(1-7)). These two opposing
proteins have been implicated in the regulation of β-cell function.
We
hypothesized that the RAS contributes to the decline of β-cell function during the
development of T2D with obesity. To test this hypothesis we first examined the
effects of whole-body deficiency of ACE2 in mice on β-cell function in vivo and in
vitro during the development of T2D. Whole-body deficiency of ACE2 resulted in
impaired β-cell adaptation to insulin resistance with HF-feeding and a reduction
of in vivo glucose-stimulated insulin secretion (GSIS) associated with reduced βcell mass and proliferation. These results demonstrate that ACE2 plays a role in
the adaptive response to hyperinsulinemia with obesity. In islets from HF-fed
mice, AngII inhibited GSIS. In mice with pancreatic-specific deletion of AT1aR,
AngII-induced inhibition of GSIS in vitro from islets of HF-fed mice was abolished.
However, there was no effect of pancreatic AT1aR-deficiency on glucose
homeostasis in vivo in HF-fed mice exhibiting pronounced hyperinsulinemia.
Notably, pancreatic weight, insulin content and basal and glucose-stimulated
insulin secretion from islets were decreased in mice with pancreatic AT1aR
deficiency. These results suggest that AT1aR may contribute to pancreatic cell
development, and also contribute to AngII-induced reductions in GSIS from islets
of HF-fed mice. Overall, these studies suggest a role for the RAS in the
regulation of β-cell function in T2D.

Keywords: Angiotensin II, angiotensin-converting enzyme 2, diabetes, β-cell,
obesity
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Section I. BACKGROUND
1.1

Type 2 diabetes (T2D): Overview

Type

2

Diabetes

(T2D)

is

a

metabolic

disorder

characterized

by

hyperglycemia. The disease is manifest as a progressive worsening of glucose
homeostasis over time as a result of insulin resistance and defects in pancreatic
β-cell function. Largely as a result of the loss of normal glucose homeostasis,
T2D

is

associated

with

long-term

complications

such

as

retinopathy,

nephropathy, peripheral neuropathy, and cardiovascular disease (CVD) (264).
1.1.1

Diagnostic criteria

Clinical diagnosis of T2D can be made from any of three assessments of
glycemia: fraction of glycated hemoglobin (HbA1C), fasting plasma glucose
(FPG), or oral glucose tolerance test (OGTT).

HbA1C is a measure of the

fraction of hemoglobin that has been non-enzymatically glycated by exposure to
glucose in the plasma. As the average amount of plasma glucose increases, the
fraction of glycated hemoglobin is increased correspondingly and the A1C
reliably reflects the mean blood sugar concentration over a 2-3 month time period
(159). Patients with A1C values between 5.7% and 6.4% are considered to be
at-risk for developing diabetes, and values > 6.5% marks a diagnosis of T2D (1).
FPG is indicative of hepatic glucose production and is measured in the
morning following an 8 hour fast. Patients with a FPG between 100-125 mg/dL
have impaired fasting glucose (IFG) and are at risk for developing T2D. A value
greater than 126 mg/dL, confirmed by repeating the test on another day, is a
positive diagnosis for overt T2D (1).

The OGTT is performed by measuring
1

plasma glucose levels two hours after oral ingestion of 75 grams of glucose.
Patients with plasma glucose between 140mg/dL and 199 mg/dL are said to
have impaired glucose tolerance (IGT) and values > 200 mg/dL meet the criteria
for a diagnosis of T2D (1). Those patients who are at risk for developing T2D are
said to have pre-diabetes.
1.1.2

Prevalence of T2D

The prevalence of diabetes in adults worldwide in 2010 was 6.4% and 439
million adults are predicted to have diabetes by 2030 (251). In 2012, 37% of the
adult US population was estimated to have pre-diabetes, while 12.3% were
estimated to have diabetes, and in persons over 65 years old the incidence
increased to 25.9% (73). The incidence of diabetes is increasing; from 1990 to
2010, the annual number of new cases in the US almost tripled. The rise in
incidence in T2D cases is associated with a rising prevalence of obesity,
decreased physical activity, and the aging US population (199). According to the
US 2012 Census Bureau, the population of people over 65 in the US is the
largest in history (and expected to double by 2050). It is clear that diabetes is a
public health epidemic – and a costly one; the estimated cost of diabetes in the
US in 2012 by the Center for Disease Control (CDC) was $245 billion.
1.1.3

Causes of T2D

The development of T2D results from a combination of genetic and
environmental factors. Evidence for a genetic component of T2D has come from
studies in twins, first degree relatives of those with T2D, and epidemiological
studies in which certain populations, such as the Pima Indians, have been found
2

to have an extremely high prevalence of T2D (19) (189). Several single gene
mutations have been identified as contributing to T2D. For example, mutations in
hepatic nuclear factor (HNF) 1α or 4α are associated with severe impairments in
insulin secretion and characterize a form of T2D termed maturity onset diabetes
of youth (MODY) (252) and T2D patients with mutations in the insulin-receptor
gene exhibit extreme insulin resistance (273).

However, monogenic forms

comprise only a minority of T2D cases.
In general, the cause of T2D is polygenic and results from an interaction
between genes and the environment. Gene association studies have identified
polymorphisms in genes expressed in adipose tissue, skeletal muscle, and βcells relating to glucose uptake and metabolism, insulin signaling, and insulin
secretion that may confer increased risk to T2D (19). Slight variations affecting
amino acid sequences, gene expression, or gene regulation can lead to an
increased susceptibility of T2D, but are not associated with the dramatic
phenotypes that are typical with monogenic cases (22). The frequency of such
polymorphisms and the subsequent interaction with environmental factors such
as age, body mass index (BMI), diet, and physical activity level can dramatically
influence an individual’s risk for developing T2D. The prevalence of obesity is
strongly linked to the prevalence of T2D (197). Since most patients with T2D are
obese (2), it is likely that obesity is the most influential environmental risk factor.
1.2

Pathogenesis of T2D: Natural history

A positive diagnosis for T2D is made when hyperglycemia becomes evident,
but the pathogenesis of diabetes begins prior to rising glycemia.

3

The

development of T2D occurs on a continuum over which pre-diabetes progresses
to overt diabetes (Figure 1.1). Three basic metabolic defects contribute to the
progression of T2D: insulin resistance, defects in insulin secretion, and increased
hepatic glucose production (80). The effects of these factors are manifest during
different stages but the combined effects contribute to disease progression
throughout the continuum.
1.2.1

Pre-diabetes

Both cross-sectional and longitudinal studies indicate that, especially in obese
patients, decreased peripheral sensitivity to insulin precedes deficits in insulin
secretion in the pathogenesis of T2D (82).

The prolonged period of onset,

termed pre-diabetes, is characterized by insulin resistance, in which the skeletal
muscle, liver, and adipose tissue become increasingly less sensitive to the
actions of insulin (223). Insulin resistance is strongly associated with obesity, but
is present even in lean patients with T2D (81). Reduced insulin action in skeletal
muscle, normally responsible for the majority of peripheral glucose uptake,
results in a significant impairment in overall glucose disposal (79). Insulin inhibits
lipolysis in adipocytes, which plays an important role in glucose homeostasis.
Regulation of lipolysis is disturbed when adipose tissues become insulin resistant
which can lead to increased plasma levels of free fatty acids (FFA). This can
augment hepatic glucose production, which is normally suppressed with
postprandial decline of plasma FFA (32). Thus, the combined effects of insulin
resistance markedly disturb glucose homeostasis.

4

Obesity is closely correlated with insulin resistance (227), which implicates
obesity as a key etiological factor in the development of T2D.

Plasma FFA

concentrations are chronically increased with obesity, mainly due to expansion of
fat mass (222).

Fatty acids and their metabolites are thought to serve as

signaling molecules that inhibit insulin signaling pathways (119). In addition, proinflammatory adipokines, such as tumor necrosis factor alpha (TNF-α) and
interleukin (IL) 6, can interfere with insulin signaling either directly or via
activation of inflammatory mediators (297) (295).
1.2.2

β-cell compensation

As insulin sensitivity declines, a higher level of insulin is needed to
achieve normal glucose homeostasis. A feedback loop exists between insulinsensitive tissues and β-cells and variations in insulin sensitivity modulate insulin
release (148). So long as insulin secretion is increased in proportion to the
severity of insulin resistance, glucose homeostasis is maintained (Figure 1.2).
Thus, the pre-diabetes phase is characterized by hyperinsulinemia but an
individual may remain asymptomatic with respect to glycemia for some time.
This adaptive response, termed β-cell compensation, is characterized by
enhanced β-cell function and increased insulin release as well as expansion of βcell mass (96).
1.2.2.1

Increased β-cell function

The major pathway for glucose stimulation of insulin release is triggered when
rising blood glucose levels reach a certain threshold and glucose enters β-cells
through type 2 glucose transporters (GLUT2) (Figure 1.3). Oxidative metabolism
5

of glucose results in an increase in the ratio of adenosine triphosphate (ATP) to
adenosine diphosphate (ADP), followed by closure of ATP-sensitive K+ (K+ATP)
channels.

This depolarizes the plasma membrane and facilitates opening of

voltage-dependent Ca2+ channels, upon which Ca2+ stimulates exocytosis of
insulin granules. Modulation of various aspects of this pathway contributes to βcell adaptation to insulin resistance, including increased glucose metabolism and
potentiation of insulin release by secretagogues and other signaling molecules
(Figure 1.3). Evidence from human studies indicates that β-cell compensation is
distinctly due to increased secretory capacity of β-cells, and not increased β-cell
glucose sensitivity (148).

However, animal studies suggest that increased

glucose metabolism may contribute to enhanced β-cell function. Specifically,
increased oxidation and utilization of glucose was observed in islets of insulin
resistant Zucker fatty rats (179). An increase in the activity of the rate-limiting
enzyme glucokinase (GK) was reported in islets isolated from hyperinsulinemic
rats (56) and chronic activation of GK improved glucose tolerance in insulin
resistant rats (303). The importance of GK is further emphasized by the fact that
knockout of pancreatic GK in mice is lethal (118) and mutations in the GK gene
are associated with MODY (125).
Increased stimulation of the insulin secretory pathway by FFA and gut
peptides, called incretins, are thought to play a role in the adaptive β-cell
response. FFAs amplify glucose-stimulated insulin release in several ways. FFA
binding to the G-protein coupled receptor GP40 initiates cellular signaling leading
to an increase in intracellular Ca2+, which in turn facilitates insulin granule
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exocytosis (140).

Additionally, fatty-acyl coenzyme A (CoA), generated by

intracellular metabolism of fatty acids, can facilitate granule exocytosis directly or
via protein kinase C (PKC) stimulation of Ca2+ release (147). The incretin
hormone glucagon-like peptide-1 (GLP-1) is produced in the intestinal mucosa
and upon binding to the GLP-1 receptor, a G-protein coupled receptor expressed
in β-cells, potentiates the insulin response to oral (versus intravenous) glucose
administration (17). The effect of GLP-1 to increase glucose-stimulated insulin
secretion was further augmented in obese, insulin resistant mice (10).

An

increase in both plasma GLP-1 and expression of GLP-1 receptor in the
pancreas was observed in a canine model of hyperinsulinemic compensation for
high-fat feeding, suggesting the importance of this peptide in the β-cell adaptive
response (284).
Pancreatic

islets

are

highly

innervated

by

both

sympathetic

and

parasympathetic neurons (5) and the insulin secretory pathway can be
augmented by acetylcholine activation of the M2 receptor or increased activity of
the β-adrenergic receptor (9).

Evidence from animal studies suggests that

increased parasympathetic activity contributes to β-cell adaptation to insulin
resistance.

Potentiation of insulin release with carbachol stimulation is

augmented in obese, insulin resistant mice (8). Additionally, vagal hyperactivity
as a result of ventromedial hypothalamic lesions caused hyperinsulinemia in rats,
and was reversed with vagotomy (26).
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1.2.2.2 Increased β-cell mass
In addition to enhanced β-cell function, the adaptive response to insulin
resistance is mediated by expansion of β-cell mass. In humans, β-cell volume is
positively correlated with weight (156) and β-cell mass is increased in obese
versus lean non-diabetic individuals (45) (93).

This is strongly supported by

animal studies, in which obesity is associated with increased β-cell mass in
Zucker fatty (ZF) rats (144) and Zucker diabetic fatty (ZDF) rats (213), ob/ob
mice (31, 280), db/db mice (104) (292) and in rodents with diet-induced obesity
(133) (209).
The majority of β-cell mass formation and expansion occurs in utero and
neonatally (40). Although the postnatal β-cell mass is relatively stable, the β-cell
population is dynamic and β-cell mass is a tightly regulated balance between
formation of new cells (via proliferation and neogenesis) and apoptosis of old
cells (35). Evidence from animal studies suggests that the adaptive response to
obesity and insulin resistance is mediated by nutrient and/or mitogen modulation
of cell cycle regulation and pro-survival pathways.
Glucose and lipids, which are increased in the bloodstream with obesity, may
act as stimulants for β-cell mass expansion.

In rats, short-term infusion of

glucose (36) (281) (261) or lipids (261) results in a significant increase in β-cell
replication and β-cell mass. Interestingly, compensatory β-cell mass expansion is
impaired in obese mice with haploinsufficiency of β-cell specific GK (274). The
effects of nutrients to modulate β-cell proliferation may be mediated in part
through GLP-1. GLP-1, released in the presence of enteric nutrients, stimulates
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the insulin secretory pathway but can also act as a mitogen and suppress
apoptosis in pancreatic cells (42). Infusion of GLP-1, or an analog, has been
shown to increase β-cell mass in normal or diabetic mice (262) (236) (152). In
streptozotocin (STZ) -treated mice, administration of the GLP-1 receptor agonist,
exendin-4, reduced β-cell apoptosis which was associated with improved
glycemia (175).
In addition to GLP-1, other mitogens that facilitate β-cell mass expansion
include both insulin and insulin growth-factor-1 (IGF). Insulin signaling in β-cells
can activate Akt, resulting in regulation of β-cell proliferation through activation of
cell cycle regulators such as cyclin D, cyclin-dependent kinase inhibitor 1
(p21Cip1), and cyclin-dependent kinase (CDK)-4 (92).

Activation of insulin-

receptor substrate-2 (IRS-2) by insulin and IGF-1 has been identified as a critical
factor for β-cell proliferation and survival (128).

The effects of IRS-2 are

mediated through activation of Akt and increased expression of pancreatic and
duodenal homeobox 1 (pdx-1) (144). IRS-2 signaling is also stimulated by the
GLP-1 receptor via the cyclic adenosine monophosphate (cAMP) response
element protein (145). The importance of IRS-2 is underscored by the fact that
deletion or disruption of the IRS-2 receptor in mice leads to eventual β-cell failure
(162).
1.2.3 Progression to overt T2D
Insulin resistance is the initiating pathogenic factor in the development of
T2D, but failure of β-cells to maintain compensation to insulin resistance
ultimately determines the onset of T2D. The transition from pre-diabetes to overt
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T2D is marked by the appearance of mild post-prandial hyperglycemia, or IGT.
Declining β-cell function leads to a relative insulin deficiency and both
postprandial and fasting blood glucose begin to rise. However, the timeframe
over which pre-diabetes progresses to overt T2D varies widely and in some
insulin resistant individuals, β-cell compensation is maintained indefinitely.
According to data from clinical trials, approximately one-third of patients with
IGT will progress to T2D (223). The identification of a population in which this
shift is most likely to occur is therefore of great interest. Data from longitudinal
studies indicate that in those destined to progress to overt T2D, β-cell
abnormalities exist prior to the emergence of hyperglycemia.

The earliest

functional defect of β-cells is thought to be a decrease in the acute insulin
response to glucose (also called first-phase insulin secretion).

Among Pima

Indians, those who progressed from normal glucose tolerance to IGT to T2D
exhibited progressive decreases in the acute insulin response compared to
nonprogressors (301).

Other studies have similarly reported that changes in

acute insulin response in follow-up visits were indicative of both glucose
tolerance status and progression to T2D. Compensation to insulin resistance
was associated with an increase in the acute insulin secretion, whereas
unchanged or decreasing acute insulin secretion was associated with IGT or
overt T2D (193) (95). These data indicate that declining insulin response to
glucose is an early indicator of β-cell dysfunction.
Following
progression

the
from

initial

appearance

pre-diabetes

to

of

impaired

diabetes
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is

glucose

marked

by

homeostasis,
progressive

hyperglycemia.

In patients with IGT, conversion to T2D is associated with

marked increases in fasting blood glucose (FBG) in follow-up visits (93). Also,
the degree of abnormal fasting glucose is correlated with the rate of progression.
In one study, 8.1% of subjects whose fasting glucose levels were between 100
and 109 mg/dL developed diabetes over an average of 29 months; of those with
fasting glucose values between 110-124 mg/dL the percentage increased to
24.3% (201).

The presence of other risk factors, such as family history,

dyslipidemia, high blood pressure, and obesity greatly influences the rate of
disease progression.
Following the onset of overt T2D, the disease is characterized by declining
insulin secretion. Hyperglycemia is exacerbated by inadequate suppression of
hepatic glucose production and further impairment of glucose uptake in insulin
resistant tissues (78). The progressive loss of both β-cell function and mass
contributes to the loss of glycemic control over time and the eventual need for
glucose-controlling medications.
1.2.4 Factors leading to β-cell failure
At the time of diagnosis of T2D, β-cell function is 25% or less of functional
capacity (234). In humans with T2D, intravenous infusion of glucose does not
result in a rapid release of insulin, despite the fact that the β-cells do contain
insulin (234). Observations in rodent models of T2D are consistent with those in
humans, in which glucose-stimulated insulin secretion is reduced both in vivo (7)
and in isolated islets (15). Impaired insulin secretion is further characterized by
a reduction in first phase insulin release, as referenced above, as well as
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abnormal pulsatile insulin release, and an increase in the circulating molar ratio
of proinsulin to insulin (163).
While changes in β-cell function during the progression to T2D are fairly well
characterized, far less is known about β-cell mass in patients with T2D due to the
difficulty in obtaining samples.

In 2003, a landmark study using autopsy

pancreata reported that β-cell volume was reduced by 40% and 63% in obese
patients with IFG and T2D, respectively, and by 41% in lean type 2 diabetics
compared to non-diabetic controls (45).

Further, the frequency of β-cell

apoptosis was increased in patients with T2D (10-fold in lean and 3-fold in
obese), but there was no difference in β-cell proliferation or neogenesis with T2D
compared to non-diabetic controls.

It was concluded that β-cell mass is

decreased with T2D, and that the cause is increased β-cell death (rather than
failure to compensate).
In a post-hoc analysis, a curvilinear relationship between β-cell volume and
FBG was reported in obese subjects with T2D or IFG in which a steep increase
in FBG was observed over a narrow window of β-cell volume (230). This is
consistent with findings from other studies in which progression of IGT to T2D
often occurred rather rapidly. This suggests that there exists a tipping point or
threshold at which β-cells collectively become overwhelmed by conspiring forces.
The mechanisms leading to β-cell failure in humans have not been fully
elucidated, but many factors that promote initial β-cell defects also contribute to
β-cell failure and eventual β-cell death. These defects have both genetic and
acquired aspects and are confounded by environmental factors, such as obesity.
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β-cell failure is not caused by a single factor, but occurs due to cumulative effects
of prolonged β-cell dysfunction in the face of genetic susceptibilities (Figure 1.4).
Factors initiating β-cell dysfunction include impaired nutrient-secretion
coupling,

mitochondrial

dysfunction,

and

β-cell

exhaustion.

Increased

carbohydrate and fat intake and subsequent nutrient availability initially serve to
instigate β-cell compensation, but over time are also implicated in leading to
acquired defects in β-cell function.

Prolonged exposure of β-cells to high

concentrations of glucose can lead to impaired insulin gene transcription,
subsequently reducing insulin secretion and can also deplete insulin granule
stores (233). Increased mitochondrial oxidation of glucose and FFA can lead to
increased production of superoxide and upregulation of uncoupling protein 2
(UCP2) (160).

The uncoupling of oxidative phosphorylation has important

consequences on ATP production, and therefore insulin secretion. Systemic and
pancreatic concentrations of reactive oxygen species (ROS) are increased with
hyperglycemia (232) (136) and ROS have been shown to both impair insulin
gene transcription (231) and interfere with the insulin secretory machinery (111).
Short-term exposure to FFAs stimulates insulin secretion, but, as with
glucose, chronically elevated levels of FFA may be detrimental to β-cell function.
Lipid infusion into rats resulted in an increase in basal insulin release and a
decrease in pancreatic insulin content, suggesting that elevated FFAs lead to
depletion of insulin stores (33). It has also been suggested that elevated FFA is
more detrimental to β-cell function with concomitant hyperglycemia due to
dysregulation of glucose and fatty acid oxidation. Via the Randle cycle, glucose
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metabolism, and thus glucose-stimulated insulin secretion, could be impaired
(81). Since malonyl-CoA levels are also high if glucose is abundant, inhibition of
FFA oxidation results in accumulation of FFA-derived acyl-CoA esters in the
cytoplasm. This pool may serve to stimulate insulin release (217), and this is
likely to occur during the earlier phase of β-cell compensation. However, acylCoA esters may contribute to formation of inflammatory signaling molecules like
ceramide, whose cumulative downstream effects on insulin secretion are
inhibitory (255).
Both chronic demand and waning production of insulin may lead to the
depletion of β-cell insulin stores. The theory that the imbalance of insulin need
with production is a factor contributing to impaired insulin secretion is termed βcell exhaustion. This theory is supported by studies in which “resting” of β-cells
in type 2 diabetics results in increased stimulatory response (117) and improved
first phase insulin secretion and reduced molar ratio of proinsulin to insulin in
type 2 diabetics (163).

Inadequate production of insulin is thought to be a

consequence of endoplasmic reticulum (ER) dysfunction.

Chronic demand,

resulting in ER stress, may lead to an increase in misfolded proinsulin (14).
Initiation of the unfolded protein response (UPR) resulting in delayed translation
may contribute to the reduction in insulin secretion. Long-term effects of ER
stress may eventually be deleterious to β-cell viability in the later stages of T2D.
Chronic metabolic stress and prolonged β-cell dysfunction precipitate β-cell
failure through purported mechanisms such as gluco- and lipotoxicity,
inflammation, islet fibrosis, ER stress, and amyloid deposition.
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Persistent

exposure of human and rodent islets to high concentrations of glucose and
saturated fatty acids are shown to have toxic effects, although the variability is
large depending on concentration, species and culture conditions (87).

The

mechanisms by which high levels of glucose and saturated fatty acids lead to
apoptosis are likely due to the initiation of an inflammatory response. Glucose
induces β-cell production of the cytokine IL-1β and the FAS receptor in islets,
leading to apoptosis of β-cells (186).

Chronic hyperglycemia can lead to the

formation of advanced glycation end products (AGE) which can cause tissue
damage through activation of inflammatory mediators (196).
Fatty acid activation of toll-like receptors (TLR) in β-cells results in the
production of cytokines, including IL-1β (34). Thus, the effects of IL-1β may be
exacerbated due to induction via glucose and fatty acids. Further, other TLR
agonists, such as certain gut flora present in obese humans and rodents may
potentiate the production of IL-1β (86).

Certain active lipids can promote

inflammatory damage directly. Various hydroxyeicosatetraenoic acids (HETEs),
produced by lipoxygenases (LO) expressed in β-cells are deleterious to both islet
function and viability (184). Conversely, inhibition of the effects of ceramide by
sphingosine-1 phosphate (S1P) both enhances glucose-stimulated insulin
secretion (GSIS) (47) and protects β-cells from cytokine-induced apoptosis (168)
in rodent studies.
In addition to initiation of apoptosis, inflammation may mediate β-cell failure
by causing islet fibrosis. It is well known that organ fibrosis is a hallmark of
chronic inflammatory diseases and leads to impaired tissue architecture and
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function.

In both humans with T2D and animal models, pancreatic tissue

sections show marked fibrosis associated with loss of β-cell function (153) (158)
(277). Disruption of islet architecture leading to impaired insulin secretion and
loss of β-cells may also result from amyloid deposits.
Islet amyloid deposits are considered a pathological hallmark of T2D and are
composed of fibrils containing aggregated islet amyloid polypeptide (IAPP, or
amylin) (134). IAPP is a 37 amino acid peptide that is co-secreted in equimolar
amounts with insulin during exocytosis from β-cells, and is inhibitory on both
insulin and glucagon secretion (298).

The role of IAPP, both in normal

physiology and in β-cell failure is not very well understood.

In post-mortem

immunohistochemical analysis of pancreatic sections, significant amyloid
deposits were identified in patients with T2D, corresponding with disrupted islet
architecture, whereas no amyloid deposits were found in control subjects (64). A
growing body of literature suggests that the role of IAPP in β-cell failure extends
beyond structural disruption and is cytotoxic. IAPP fibrils or small oligomeric
aggregates have been shown to be toxic to human and rat islets in vitro (180)
and this is consistent with human studies in which amyloid deposition is
associated with reduced β-cell mass (134).

However, mechanistic insight is

limited because pathological deposition of islet amyloid does not occur in the
rodents, which are commonly used in diabetes research (299). IAPP aggregates
have been shown to disrupt cell membranes (143), and it has been suggested
that IAPP aggregates crowd the ER membrane, facilitating ER stress and
dysfunction (83).
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Induction of the UPR due to ER stress may initially result in reduced insulin
biosynthesis, but chronic activation of the ER stress response has far more
detrimental effects. Chronic ER stress promotes apoptosis via the UPR-related
transcription factor CHOP, and CHOP deletion improves β-cell mass and
glycemic controls in mouse models of T2D (257). In addition, ER stress has
been shown to activate IL-1β independently of the UPR in vitro (194).
It is clear that individual factors contributing to β-cell damage are
compounded to create an effect that severely impacts β-cell sustainability.
Slight genetic susceptibilities can dramatically influence the tipping point at which
β-cell function can no longer be maintained. In humans, several polymorphisms
in genes that have varying roles in regulation of adipocyte function, cellular
energy metabolism, and insulin secretion and gene expression have been
associated with increased risk for T2D.

Notable genes include peroxisome

proliferator-activated receptor gamma (PPAR-γ), PPAR-γ coactivator 1-α
(PCG1α), transcription factor Kruppel-like factor 11 (KLF11), and potassium
inwardly-rectifying

channel,

subfamily

J,

member

11

(KCNJ11)

(218).

Polymorphisms in genes whose function contribute to metabolic adaptation,
coupled with the metabolic pressures of obesity, lead to increased risk for T2D.
1.3

Mouse models of T2D

Several mouse models of T2D are routinely used in basic science research,
but none exactly mimic the human condition due to the complex nature of the
pathogenesis of diabetes.

Mouse models for T2D typically involve the

development of obesity, either through diet or due to genetic manipulation.
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1.3.1 Genetic mouse models
The most widely used genetic mouse models are ob/ob and db/db mice,
which lack the genes for leptin and the leptin receptor, respectively. Although
monogenetic forms of T2D represent the minority in humans, these strains are
useful in research because they develop robust obesity, which reflects the
human condition in which obesity is closely related to the development of T2D.
In a 1978 publication by Coleman of The Jackson Laboratory (70), the
phenotypes of these two mouse models are described. Both strains develop
insulin resistance, hyperinsulinemia, and impaired glucose homeostasis within
the first month of age. However, the two strains display a marked phenotypic
difference in β-cell function.

Ob/ob mice exhibit rather robust β-cell

compensation, characterized by increased β-cell mass and sustained insulin
secretion. In contrast, compensation to insulin resistance is not maintained in
db/db mice. By 3-4 months of age, db/db mice exhibit progressive loss of β-cell
function and β-cell mass, eventually manifest as hypoinsulinemia and
hyperglycemia. The mice develop ketosis and die by 8-10 months of age. Use
of the db/db mouse is therefore suitable for research focused on β-cell failure,
while ob/ob mice are better suited for studies targeting insulin resistance.
Since the etiology of T2D in humans is most polygenetic, use of polygenetic
strains, such as KK, New Zealand Obese (NZO), and TallyHo, has become more
widespread.

These strains develop obesity and display varying degrees of

glucose intolerance and β-cell dysfunction (154). Polygenetic models of T2D
have been used in studies investigating the interplay of obesity and T2D or to
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study diabetic complications.

However, a major drawback of these types of

models is the lack of a wild-type control.
1.3.2 Diet-induced obesity
Diet-induced obesity (DIO) in the absence of genetic modifications is widely
used to identify the environmental effects of obesity on the development of T2D.
DIO, first described in 1988 in C57BL/6 mice, leads to robust obesity
accompanied by insulin resistance, hyperinsulinemia, and impaired glucose
homeostasis (266).

DIO is also referred to as high-fat (HF) feeding because

diets are comprised of a very large percentage of calories that are derived from
fat (45-60%, compared to 15-20% as in standard rodent diets). In addition, diets
are usually high in simple sugars, such as maltodextrin and/or sucrose, and
sometimes contain added cholesterol to mimic diets that lead to obesity in
humans. DIO is often used in combination with a specific gene knockout in order
to evoke the emergence of a phenotype in response to metabolic challenge.
This approach is useful for the identification of candidate genes that cause
susceptibility to T2D in humans.

However, consideration of the background

strain of the mouse is important since there can be wide variations in response to
DIO between mouse strains.
DIO in C57BL/6 mice is widely used in studies of T2D and other metabolic
disorders. Obese C57BL/6 mice become markedly insulin resistant and glucose
intolerant compared to non-obese controls.

This strain also demonstrates a

robust capacity for compensation to diet-induced insulin resistance as evidenced
by increased β-cell mass and islet insulin content (71) and hyperinsulinemia that
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is sustained through at least 10 months on diet (7). No evidence has been
published suggesting that obese C57BL/6 mice exhibit β-cell failure, although
HF-feeding has been shown to reduce the acute secretory response to glucose
both in vitro and in vivo (7), (212).
C57BL/6 mice are said to be moderately prone to diet-induced diabetes
compared to other strains.

HF-fed C57BL/6 mice exhibit intermediate

phenotypes with respect to GSIS in vitro and in vivo, as well as an intermediate
phenotype for the development of glucose intolerance and insulin resistance
compared to DBA, FVB, and 129 strains (23). The C57NLKS/J strain, a variation
of C57BL/6, has a greater susceptibility to β-cell failure, especially when crossed
onto the db/db strain (66). The A/J strain is considered to be “diabetes-resistant”
in that HF-feeding is not associated with the development of insulin resistance
and glucose intolerance (66).
1.4

Therapies for T2D

The overall objective for treatment of T2D depends on the level of disease
progression. Randomized controlled trials (RCTs) have shown that in individuals
with pre-diabetes, the rate of T2D onset can be significantly decreased with
particular interventions (264). The Diabetes Prevention Program (DPP) was a
major clinical research study in the US in which lifestyle intervention or treatment
with the diabetes drug metformin could prevent or delay the onset of T2D in
overweight persons with pre-diabetes.

Intensive counseling and a modest

reduction of body weight through dietary changes coupled with increased
physical activity was shown to reduce the risk of developing diabetes by 58%,
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and metformin decreased risk by 31% (157).

Follow-up from this and other

studies indicate that lifestyle modification is cost-effective and that risk reduction
associated with weight loss is sustained over a number of years. Since β-cell
failure is degenerative, the first line of treatment for T2D is prevention. However,
despite preventative therapies, many patients still progress to T2D. Moreover,
effectiveness of lifestyle interventions to delay or prevent the onset of T2D is
limited since both program compliance and maintenance following the
interventions are notoriously difficult to achieve.
Following diagnosis, the primary treatment objective is glycemic control,
achieved using pharmacological therapy in addition to healthy eating, weight
control, and increased physical activity. Mono-drug therapy with metformin is the
preferred initial pharmacological agent per the American Diabetes Association
(ADA) but glycemic control often requires two- or three-drug combinations.
Metformin improves glycemia by suppressing hepatic glucose output and it also
improves insulin sensitivity (110). Metformin poses a low risk for hypoglycemia
and for weight gain, however it has no effect to improve β-cell function.
Thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, are also
effective insulin sensitizers. TZDs act by agonizing PPAR-γ to improve insulin
sensitivity (289) and have a low risk for hypoglycemia, but may cause weight
gain and fluid retention (264). However, in addition to acting as effective insulin
sensitizers, TZDs may preserve β-cell function and morphology (108).
Some diabetes medications lower blood glucose by acting as insulin
secretagogues. Sulfonylureas stimulate insulin release from β-cells and work by
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binding to β-cell KATP channels and facilitating membrane depolarization (3).
These drugs, however, do promote weight gain and some studies suggest they
may be deleterious to long-term β-cell viability (96). GLP-1 mimetics or GLP-1
receptor agonists are emerging as a promising class of drugs for the treatment of
T2D.

These drugs stimulate post-prandial insulin release, inhibit glucagon

secretion and delay gastric emptying.

In addition to being low risk for

hypoglycemia, these drugs may beneficially augment β-cell function. A related
class of drugs are those that prevent the cleavage of GLP-1, called dipeptidyl
peptidase-4 (DPP-4) inhibitors, which thereby promote the beneficial effects of
GLP-1 on β-cell function (90).
Other anti-hyperglycemic drugs include α-glucosidase inhibitors and sodiumglucose cotransporter (SGLT)-2 inhibitors.

α-glucosidase inhibitors inhibit

carbohydrate absorption through competitive inhibition of carbohydrate digestive
enzymes, and have recently been shown to augment incretin secretion (316).
SGLT-2 inhibitors reduce hyperglycemia by increasing urinary glucose excretion
independently of insulin secretion or action (75).

Despite the variety of

pharmacological treatment options available, most clinical trials indicate that loss
of glycemic control over time is inevitable, due to the progressive nature of β-cell
failure, and insulin therapy is eventually needed for many patients with T2D (96).
1.5

T2D: Link to the renin-angiotensin system (RAS)

Patients with T2D are at an increased risk for CVD morbidities and
mortalities. According to the CDC, diabetes is an independent risk factor for
CVD and among individuals with diabetes, the risk for stroke and other
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cardiovascular events is doubled. Further, CVD is the leading cause of death in
diabetics. Pre-diabetes or T2D is often concomitant with CVD risk factors, such
as obesity, hypertension, and dyslipidemia (264).

Interestingly, all of these

conditions have been associated with increased activity of the renin-angiotensin
system (RAS).
1.5.1

Overview of the RAS

The RAS is an endocrine system classically associated with systemic
regulation of blood pressure and fluid homeostasis mediated by various
angiotensin peptides. An overview of the components of the RAS is depicted in
Figure 1.5. Activation of the RAS occurs when the renal-derived protease, renin,
cleaves angiotensinogen (AGT), a large, primarily hepatic-derived protein, to
generate the biologically inactive decapeptide angiotensin I (AngI). Hydrolysis of
AngI by the lung-derived carboxy-dipeptidase angiotensin-converting enzyme
(ACE) results in the formation of angiotensin II (AngII). AngII, considered to be
the main bioactive peptide of the RAS, exerts its effects through the two Gprotein coupled angiotensin II type 1 (AT1R) and type 2 (AT2R) receptors.
In addition to AngII, several other peptides can be generated that have
biological activity.
angiotensin

2-8

AngII can be catabolized by aminopeptidases to generate
(AngIII)

and

angiotensin

3-8

(AngIV)

(161)

and

by

decarboxylation to generate angiotensin A (AngA) (142). AngIII and AngA have
been demonstrated to have pressor responses capable of affecting blood
pressure similar to AngII (226) (142) (308).

AngIV, which binds to the

angiotensin II type 4 receptor (AT4R), also known as the insulin-regulated
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aminopeptidase receptor (IRAP), is thought to play a role in facilitation of learning
and memory (53). Interestingly, IRAP has been shown to play a role in the
trafficking of glucose transporter type 4 (GLUT4) vesicles, although the role of
IRAP in glucose uptake in insulin-sensitive tissues has not been well defined
(293).
1.5.1.1

Angiotensin II (AngII) receptors

The AT1R and AT2R share 34% homology at the protein level and AngII
binds to each with similar affinity (206). However, the tissue distribution and
expression density of AT1R is diverse, while that of AT2R is limited (and higher
during development). The majority of the well-known cardiovascular effects of
AngII are mediated by AT1R. These include vasoconstriction of vascular smooth
muscle, stimulation of aldosterone release from the adrenal cortex, and activation
of the sympathetic nervous system.

These actions of AngII contribute to its

ability to increase blood pressure and fluid volume, but AngII also acts at AT1R
to stimulate the release of prostaglandins, inflammatory mediators, and ROS,
and is involved in cellular growth and proliferation.
Rodents express two subtypes of the AT1R, AT1a and AT1b, which share
94% homology (126). The rodent AT1aR subtype is thought to be most similar to
the human AT1R based on tissue distribution and physiologic effects.

Rat

AT1aR shares 95% homology with human AT1R (24) and the tissue distribution
of AT1R in humans and rodents is similar. In humans and rodents, AT1R/AT1aR
expression includes kidney, lung, liver, gonads, adrenal gland, brain, adipose
tissue, and vascular smooth muscle (44) (52) (85). Rodent AT1bR distribution is

24

more limited and includes kidney, testes, adrenal and anterior pituitary glands,
and mesenteric resistance vessels (44) (85) (318). In rodents, deletion of AT1aR
is associated with reduced blood pressure, which is consistent with
pharmacological blockade of AT1R in humans (139).

Deletion of AT1bR in

rodents has no effect on blood pressure (57).
The functional role of the AT2R is not well understood. The expression of
AT2R is high in fetal tissues but declines prior to birth, suggesting a role for
AT2R during fetal development, (115). However, growth and development are
not impaired in AT2R-knockout mice although the drinking response is
decreased and the vasopressor response to AngII is increased (126) (135).
Post-natal expression of AT2R has been demonstrated in brain, heart, adrenal
medulla, kidney, and reproductive tissues (282).

Although AT2R knockout

animals lack a strong phenotype, exposure to disease models tends to result in a
more severe response suggesting that AT2R may function in a protective manner
(290) (265). Additionally, AT2R stimulation has been shown to promote neuronal
differentiation and regeneration after injury (182).
The signal transduction pathways and subsequent physiological effects of the
angiotensin receptors differ markedly.

AT1R (including AT1aR and AT1bR

subtypes) is antagonized by biphenylimidazoles, such as losartan, candesartan,
and valsartan, which selectively bind the AT1R with high affinity (43). These
drugs, also called angiotensin type 1 receptor blockers (ARBs) are used clinically
to inhibit the effects of AngII on blood pressure and fluid retention. In contrast,

25

tetrahydroimidazolpyridines, such as PD123319 and PD123177, selectively
antagonize the AT2R (85).
The most well-described signal transduction pathway for the classical effects
of AT1R includes Gq/11 coupled activation of phospholipase C (PLC) with
subsequent inositol triphosphate (IP3)-mediated release of intracellular calcium
stores leading to vasoconstriction in vascular smooth muscle cells (210).
Vasoconstriction is also mediated by PLC via diacylglycerol (DAG), by Gimediated inhibition of adenylate cyclase, and by facilitating opening of cAMP-Ltype calcium channels (85).

Gq coupling also simulates prostaglandin release

via activation of phospholipase A2 (PLA) and phospholipase D (PLD), and
mediates growth and proliferation via mitogen-activated kinases (85).

Many of

the effects of AT2R are thought to be contrary to that of AT1R. These include
vasodilation via stimulation of nitric oxide (NO) production (72) and inhibition of
proliferation, (263) possibly via G-coupled protein-mediated activation of
phosphatases (85).
1.5.1.2 Angiotensin-converting enzyme 2 (ACE2)
In 2000 two groups described a newly discovered component of the RAS, a
carboxy-peptidase called angiotensin converting enzyme 2 (ACE2) that shares
42% sequence homology with ACE (88) (278). ACE2 is a zinc metalloprotease
that cleaves the c-terminal amino acid from AngII to generate the heptapeptide
angiotensin 1-7 (Ang-(1-7)) (278). The effects of Ang-(1-7) are mediated by the
Mas receptor (MasR) (240), and are generally thought to oppose that of AngII
(94). ACE2 can also hydrolyze AngI, although with less affinity than for AngII, to
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generate angiotensin 1-9 (Ang-(1-9)) (288) with subsequent hydrolysis by ACE
resulting in Ang-(1-7) (296). Also shown to have effects that oppose AngII is the
newly characterized peptide alamandine, which is generated either directly from
Ang-(1-7) or by hydrolysis of AngA by ACE2 (167). The discovery of ACE2 and
the characterization of the ACE2/Ang-(1-7)/MasR axis has led to the concept that
the RAS has two active arms whose effects oppose each other, with ACE2 acting
as a negative physiological regulator.
1.5.2

Pharmacologic inhibition of the RAS: Effect on new-onset

diabetes (NOD)
Pharmacological inhibition of the RAS is achieved either by preventing the
formation of AngII with either renin or ACE inhibitors, or blocking the effects of
AngII with ARBs.

Drugs that inhibit the RAS are first-line treatments for

hypertension. Over the last decade, findings from RCTs support a benefit of
ACE inhibitors or ARBs to improve cardiovascular outcomes beyond that of blood
pressure control in both diabetic and non-diabetic patients (313) (76) (97). In
addition to improved cardiovascular protection, some studies suggest that ACE
inhibitors or ARBs may protect against the development of T2D (Table 1.1).
One of the first studies to report a beneficial effect of RAS inhibition on
development of diabetes was the Heart Outcomes Prevention Evaluation (HOPE)
study. In patients at high risk for cardiovascular events, the ACE inhibitor ramipril
was associated with reduced rates of death, myocardial infarction, and stroke
compared to placebo; as a secondary outcome ramipril was associated with
fewer cases of new onset diabetes (NOD) (313).
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A post-hoc analysis was

published the following year reporting a 34% reduction in risk of developing NOD
in patients treated with ramipril versus placebo (312).

Similar findings were

reported in several other RCTs in which the efficacy of ACE inhibitors or ARBS to
improve cardiovascular outcomes was the primary endpoint. However, results
are mixed as some trials reported no effect of RAS inhibition to reduce the
incidence of T2D. Further, few RCTs have been done in which prevention or
delay of NOD with use of ACE inhibitors or ARBs was a primary endpoint.
The Diabetes Reduction Assessment with Ramipril and Rosiglizatone
Medication (DREAM) study was designed on the heels of the HOPE trial to
evaluate whether ramipril (and, separately, rosiglizatone) reduces the risk of
diabetes in people with IFG or IGT but who are at low risk for CVD. Results of
the study were disappointing in that ramipril was shown to have no significant
effect versus placebo on the incidence of NOD; a moderate improvement of
glycemia with ramipril treatment was the only positive finding after three years of
follow-up (37). Roziglitazone, however, was shown to substantially reduce the
incidence of NOD (109).
The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes
Research (NAVIGATOR) study was the second RCT in which diabetes was the
primary outcome. Patients displaying IGT and one or more cardiovascular risk
factors were given valsartan or placebo (and separately, nateglinide or placebo)
with concomitant lifestyle modification and follow-up occurred over a mean of 5
years. Valsartan was shown to have a 14% reduction in risk of developing NOD
compared to placebo (192) and nateglinide did not reduce the incidence of NOD
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(192). Results from this study with respect to valsartan’s efficacy to reduce NOD
were positive but modest. The actual effects of valsartan are difficult to interpret
since lifestyle modification was a goal for both groups and concomitant use of
additional ACE inhibitors and ARBs at the last visit was significantly greater in the
placebo group.
1.5.3

RAS and glucose homeostasis

The underlying mechanisms linking the RAS to diabetes are incompletely
understood, but evidence from human and animal studies supports that
activation of the RAS is associated with insulin resistance and β-cell dysfunction.
Components of the RAS, including those required for the synthesis of AngII, have
been identified in a myriad of tissue types including heart, brain, kidney, skeletal
muscle, adipose tissue, and pancreas. This has given rise to the concept of a
local tissue RAS that may play a role in normal organ function and AngII has
been shown to have paracrine or autocrine effects resulting in the promotion of
inflammation, fibrosis, oxidative stress, cell proliferation, and apoptosis (220).
Further, activation of the RAS has been implicated in organ dysfunction and
changes in organ structure in a variety of diseases, including diabetes,
independent of blood pressure.

Local AngII production has been shown to

induce blood-pressure independent cardiac hypertrophy (191) and overactivity of
the renal RAS contributes to fibrosis and end-organ damage (286). The profibrotic and pro-inflammatory actions of AngII have been linked to the
macrovascular complications of diabetes (113) as well as diabetic nephropathy
(317).
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1.5.3.1 The RAS and insulin sensitivity
Studies in humans, animals, and cells support a role for AngII in the
development of insulin resistance through impaired function of both skeletal
muscle and adipose tissue. Early studies implicating the RAS in impaired insulin
resistance were focused on the hemodynamic effects of AngII.

In animals,

pressor doses of AngII increased insulin resistance and decreased glucose
uptake (229) (205).

Conversely, in human studies improvements in glucose

disposal and insulin sensitivity with ACE inhibitors were attributed to a reduction
in the vasoconstrictive effects of AngII (198) (208) (268). More recently, AngII
has been implicated in impaired insulin sensitivity and reduced glucose disposal
through direct inhibition of insulin signaling in skeletal muscle (129) (256) (129).
Several studies suggest that AngII-mediated insulin resistance is due to AngII
activation of NADPH oxidase and the production of ROS (30) (165) which inhibits
phosphatidylinositol 3-kinase (PI3K) recruitment of GLUT4 (294).
1.5.3.2 Obesity and the RAS
Rodent and human adipose tissue expresses all the components of the RAS
required for the synthesis of AngII (Table 1.2). This local RAS is upregulated
with obesity (39) and may contribute to adipose dysfunction. Both increased
production of adipokines and impaired adipocyte differentiation leading to
adipocyte hypertrophy are thought to be deleterious to insulin sensitivity. The
role of the RAS on adipocyte differentiation remains controversial. It has been
postulated that AngII has an inhibitory effect on lipolysis and adipogenesis via
AT1R (114) (100) while other studies report AngII enhances adipocyte
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differentiation (239) and is AT1R-mediated (244).

Interestingly, in a mouse

model of adipocyte-specific deficiency of AT1aR, deletion of AT1aR had no effect
on adipocyte differentiation or lipolysis in obese mice, and did not improve
glucose tolerance, but was associated with reduced differentiation and increased
adipocyte hypertrophy in lean mice (220). In rodents, improved insulin sensitivity
with ARB treatment was associated with increased adipocyte differentiation as
well as reduced inflammatory markers in adipose tissue and increased gene
expression of adiponectin and PPARγ (169). It is possible that the differential
effects of genetic versus pharmacological inhibition of the AT1R may be
attributed to the fact that some ARBs have PPAR-γ agonistic effects.
Perhaps more impactful on the development of diabetes than possible effects
of local adipose RAS on insulin sensitivity is the fact that obesity is associated
with an increase in the systemic RAS. In obese rodents, systemic levels of AGT
and angiotensin peptides (including AngII) are increased, corresponding with the
development of hypertension (39) (121). Further, adipocyte-specific deficiency of
AGT ablated obesity-hypertension and was associated with a reduction in
circulating AngII (309). These results suggest that adipose tissue is a major
source of systemic AngII in obesity. This has significant implications in the role
of the RAS to promote the development of T2D given the association between
obesity and T2D.
1.5.4

A tissue pancreatic RAS

The endocrine pancreas expresses several components of the RAS (Table
1.2), including AT1R, suggesting that AngII may act directly at the pancreas to
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regulate β-cell function. Further, components of the RAS are upregulated with
hyperglycemia in rodent and human islets (61) (185). In mice, AngII has been
shown to reduce insulin release and biosynthesis in islets (166) (61) and infusion
of AngII promoted hyperglycemia and reduced GSIS (58). Conflicting reports of
the effects of AngII on insulin secretion do exist, as AngII has been demonstrated
to increase insulin release both in vitro and in vivo (224) (112).

However,

blockade of the RAS using ARBs or ACE inhibitors in rodent models of T2D
consistently improves overall glucose homeostasis (277) (61) (69) (235) (98).
Taken together, these data support a role for AngII to modulate glucose
homeostasis, however the role of the pancreatic RAS in progressive β-cell failure
in T2D is unknown.
1.5.4.1 Regulation of β-cell function by AngII
AngII has been implicated in β-cell dysfunction in vitro and in animal studies
in vivo by increasing oxidative stress, inflammation, and fibrosis in islets. In
mouse islets, as in skeletal muscle, AngII induced superoxide generation via
NADPH oxidase activation (132). In db/db mice, AT1R antagonism reduced islet
mRNA expression of both NADPH oxidase and UCP2 and was associated with
improved insulin secretion and reduced apoptosis of β-cells (62).

In addition to

increasing the production of ROS, AngII is also purported to stimulate the release
of inflammatory mediators, such as IL-1β, monocyte chemoattractant protein-1
(MCP-1), IL-6, and IL-8 in mouse islets (59) (246). Recently, the deleterious
effects of AngII infusion into HF-fed mice to induce islet inflammation and
decreased GSIS were reversed with inhibition of IL-1β (246).
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Given the

previously published role of IL-1β as a mediator of the negative effects of glucoand liptoxicity on β-cell function and survival, this study provides an important link
between AngII and the inflammatory response associated with glucotoxicity.
Further, in human islets cultured in high glucose, where mRNA expression of
AT1R and AGT was increased, losartan prevented deleterious effects of
glucotoxicity (185). Finally, blockade of the RAS attenuated islet fibrosis and
improved insulin secretion in both ZDF rats (277) and db/db mice (250).
Although most of the effects of AngII to regulate β-cell function are
demonstrated as AT1R-mediated, there is some evidence for a role of AT2R. In
contrast to that of AT1R, AngII stimulation of AT2R may function as an
insulinotropic mediator.

In rats, insulin secretion was increased with

administration of AngII, AngII plus losartan, or an AT2R agonist, and this effect
was abolished with AT2R antagonism (249).

Recently AT2R has also been

reported to regulate the development of the endocrine pancreas. In human fetal
pancreatic progenitor cells, AT2R was shown to be a key mediator of AngIIinduced upregulation of transcription factors important in β-cell development
(171). The same group further reported that AT2R, but not AT1R, blockade
during embryonic development in mice impaired β-cell development and was
associated with impaired insulin secretion in islets isolated from neonatal pups
(172).
1.5.4.2 Regulation of β-cell function by ACE2
While AngII acting through the AT1R is generally thought to reduce
pancreatic function and overall glucose homeostasis, recent studies suggest that
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the opposite many be true of Ang-(1-7). In a transgenic rat model expressing an
Ang-(1-7)-producing fusion protein, increased circulating Ang-(1-7) enhanced
glucose tolerance and insulin sensitivity (242). Further studies in rat models of
T2D demonstrated that an oral formulation of Ang-(1-7) improved peripheral
glucose uptake and insulin resistance resulting in improved glycemia (207) (243).
Thus, where AngII may promote the development of T2D, Ang-1-7 may be
protective. Since ACE2 is the critical regulator of the relative abundance of these
two peptides, this suggests that ACE2 may play a role in glucose homeostasis.
ACE2 was identified in islets of mice (203), rats (91), and humans (211).
Mice with a whole body deficiency of ACE2 become progressively glucose
intolerant with age and display impairments in insulin secretion, yet remain
sensitive to insulin (203). In addition, MasR expression was demonstrated in
mouse endocrine and exocrine pancreas (29), suggesting a role for the Ang-(17)/MasR axis in the regulation of β-cell function.

Adenoviral-mediated

overexpression of ACE2 in pancreas of db/db mice increased islet insulin
content, reduced β-cell apoptosis, and improved glucose tolerance (28). These
effects were attributed to ACE2-mediated production of Ang-(1-7), since the
beneficial effects of ACE2 overexpression were prevented with blockade of the
MasR.
Adenoviral overexpression of ACE2 in the pancreas also prevented the
deleterious effects of AngII infusion on glucose homeostasis into mice (58).
Therefore, the protective effects of ACE2 may be a result of both increased Ang(1-7) and decreased AngII.

Interestingly, protein expression of ACE2 was
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reduced in islets of AngII-infused mice with impaired glycemia (58). A reduction
in ACE2 protein was also observed in islets from db/db mice at 16 weeks of age
compared to 8 weeks of age (28). These data suggest that reduced function of
the ACE2/Ang-(1-7)/MasR axis may be one component by which RAS overactivity facilitates the development of T2D.
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Table 1.1 Effects of RAS antagonists on the development of T2D
Study name
Effect
Reference
(312)
Ramipril treatment reduces the risk of new-onset
HOPE
diabetes (NOD) in 5720 patients at risk for CV
events over 4.5 years (relative risk 0.66; ramipril
vs. placebo treatments).
Ramipril treatment had no significant effect on the (37)
DREAM
development of NOD, however it did increase
regression to normoglycemia compared to placebo
in study of 5269 patients
Valsartan treatment reduced the development of
(192)
NAVIGATOR
NOD by 14% in a study including 9306 patients
with impaired glucose tolerance and other
cardiovascular risk factors over 5 years
Of the 291 non-diabetic paitents included in the
(287)
SOLVD
SOLVD trial, 5.9% of those given enalapril
compared to 22.4% of those given placebo
developed NOD
Of the 10,413 non-diabetic patients included in the (202)
CAPPP
CAPPP trial, there was a 14% reduction in NOD in
captopril-treated patients
Patients without diabetes at baseline receiving
(20)
ALLHAT
lisinopril instead of chlorthalidone had reduced
fasting glucose and through 2 years of follow-up
had significantly reduced NOD (odds ratio 0.55)
Over 4.8 years, losartan treatment significantly
(178)
LIFE
reduced the incidence of NOD compared to
atenolol (relative risk 0.75) in 7998 hypertensive
patients with left ventricular hypertrophy
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Table 1.2 Pancreatic components of the RAS
RAS Component

Species

Cell Type/Location

Renin

Human

Mouse

β-cells
Islets: connective tissue
surrounding blood vessels and
in reticular fibers
AR42J – A pancreatic acinar
cell line
Pancreas
α-cells
Islets: microvasculature, islet
periphery
Pancreas
Acini and islets
Islets
Islets
β-cells
β-cells
Colocalized with somatostatinproducing cells
Islets (β-cells)

Mouse

Endocrine and exocrine

Rat
AGT
ACE

ACE2

AT1Receptor
AT2Receptor

Mas Receptor

Canine
Rat
Rat
Rat
Rat
Rat
Mouse
Human
Mouse
Rat
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Reference
(271)

(54)
(55)
(228)
(277)
(138)
(277)
(91)
(28)
(271).
(166)
(304)
(60)
(29)

Figure 1.1

The natural history of the development of T2D: progression

from impaired glucose tolerance to overt T2D, from Ramlo-Halsted and
Edelman, 2000
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Figure

1.2

Metabolic

changes

during

the

development

of

T2D.

Insulin secretion and insulin sensitivity are related. As an individual becomes
more insulin resistant (by moving from point A to point B), insulin secretion
increases and normo-glucose tolerance (NGT) is maintained.

A failure to

compensate by increasing the insulin secretion results initially in impaired
glucose tolerance (IGT; point C) and ultimately in type 2 DM (point D). From
Fauci et al, Harrison’s Principles of Internal Medicine, 17th Edition, McGraw-Hill,
2008
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Figure 1.3

Regulation of insulin secretion; From Berne et al, Physiology 5th

Edition, Mosby, 2004
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Figure 1.4 Factors contributing to β-cell failure; from Popa et al, Beta-Cell
Function and Failure in Type 2 Diabetes, Type 2 Diabetes Prof. Kazuko Masuo
(Editor), 2013
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Figure 1.5 Schematic overview of the renin-angiotensin system.

Figure 1.5 Schematic overview of the renin-angiotensin system. The
precursor peptide, angiotensinogen, is cleaved by renin to form the decapeptide
angiotensin I.

The catalytic activity of renin increases when bound to the

(pro)renin receptor [(P)RR] and furthermore, the otherwise inactive prorenin can
become catalytically active when bound to the (P)RR.

The dipeptidase

angiotensin converting enzyme (ACE) cleaves angiotensin I to form the
octapeptide angiotensin II (AngII), the central active component of this system.
AngII can be catabolized by angiotensin converting enzyme 2 (ACE2) into
angiotensin1-7 (Ang1-7), another active peptide of this system which typically
opposes the actions of AngII. AngII can also be cleaved into smaller fragments,
such as angiotensin III and angiotensin IV by aminopeptidases A and M,
respectively. Angiotensin A (AngA) is generated from AngII by decarboxylation.
ACE2 can convert AngA into alamandine, which acts at the Mrg receptor. Most
effects of AngII are mediated by the angiotensin type 1a receptor (AT1R),
however AngII can also bind to the angiotensin type 2 receptor (AT2R) which
generally exhibits opposing effects to those at the AT1R. Ang1-7 acts via the
Mas

receptor

and

angiotensin

IV

can

bind

to

the

insulin-regulated

aminopeptidase receptors (IRAP). Adapted from Putnam et al 2012.
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STATEMENT OF THE PROBLEM
Type 2 diabetes (T2D) is a metabolic disorder characterized by an initial
adaptive increase in insulin secretion in response to insulin resistance followed
by a progressive decline in cell function leading to loss of glycemic control.
Obesity plays a significant role in T2D by contributing to the development of
insulin resistance and both facilitating and exacerbating β-cell dysfunction. In
2012, the number of adults in the United States with diabetes or pre-diabetes
was estimated at 29 million and 86 million, respectively, and more than 78 million
American adults are obese.

People with T2D are at an increased risk for

cardiovascular disease (CVD), and CVD is the major cause of death in diabetics.
T2D is a public health epidemic and the identification of mechanisms that link
obesity, T2D, and CVD is a major focus of current research.
In clinical trials, drugs that inhibit the renin-angiotensin system (RAS) have
been associated with a decrease in the risk of developing T2D.

However,

mechanisms by which the RAS contributes to the development of T2D remain
unclear. Our lab and others have demonstrated that obesity is associated with
an increase in the plasma concentrations of angiotensin II (AngII).

The

endocrine pancreas expresses several components of the RAS, including
angiotensin type 1 receptors (AT1Rs). AngII has been demonstrated in animal
studies to impair glucose homeostasis, inhibit insulin secretion, and promote the
formation of reactive oxygen species and inflammatory mediators in isolated
pancreatic islets. Pharmacologic blockade of the RAS in animal models of T2D
improves glucose tolerance and insulin resistance.
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However, many of these

studies employ whole body AT1R blockade, making it difficult to define the direct
effect of AngII actions at AT1R on pancreatic islets. Moreover, mechanisms for
the observed benefits of RAS blockade, specifically whether they improve insulin
sensitivity, as opposed to improving β-cell function, have not been well defined.
Recent studies indicate a role for angiotensin converting-enzyme 2 (ACE2) in
the regulation of β-cell function. ACE2 is a negative RAS regulator in that the
enzyme cleaves the vasoconstrictor, AngII, to generate the vasodilator,
angiotensin-1-7 (Ang-1-7). Mice with whole body deficiency of ACE2 display
moderate impairments in glucose homeostasis. Conversely, overexpression of
ACE2 in the pancreas was shown to improve insulin secretion and glycemia by
increasing Ang-(1-7) effects at Mas receptors in the endocrine pancreas of db/db
diabetic mice.

In separate studies, ACE2 overexpression prevented the

deleterious effects of AngII infusion on glucose homeostasis in mice.

While

these results implicate ACE2 in the regulation of whole body glucose
homeostasis, the role of ACE2 in the regulation of β-cell function in the
progression of T2D is not well defined.
It is well accepted that activation of the local and systemic RAS contribute to
CVD. An emerging body of evidence suggests that over-activity of the RAS is a
common thread in the pathophysiology of obesity, CVD, and T2D. Our focus
was to define the role of two opposing proteins of the RAS, namely AT1R and
ACE2, on the regulation of β-cell function and glucose stimulated insulin
secretion (GSIS) in vitro and in vivo. We chose these RAS components as they
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have both been implicated in T2D, and since both may serve as potential
therapeutic targets (AT1R blockade, ACE2 activation) in the treatment of T2D.
We used high fat (HF) diet-induced obese mice with whole body ACE2
deficiency to define the enzyme’s effects on in vivo and in vitro GSIS.

For

studies on AT1R, we created a mouse model of pancreas-specific deficiency of
the AT1aR to be used in conjunction with diet-induced obesity to gain a better
understanding of the AngII/AT1aR-mediated effects on β-cell function.

The

central hypothesis of these studies is that the RAS contributes to the decline of βcell function during the development of T2D. Specifically, in Aim 1 we tested the
hypothesis that ACE2 deficiency impairs in vitro and in vivo GSIS through deficits
in β-cell function in HF-fed mice.

In Aim 2, we tested the hypothesis that

pancreatic AT1aR deficiency will protect against impaired in vitro and in vivo
GSIS in HF-fed mice. The following aims were designed to test this hypothesis:
Specific Aim 1: Determine the effect of whole body deficiency of ACE2 on
glucose homeostasis in mice during the development of T2D.
A. Characterize the temporal effect of ACE2 deficiency on β-cell function
in lean and obese mice.
B. Determine the relative roles of increased AngII and decreased Ang-1-7
on glucose homeostasis in obese mice with ACE2 deficiency.
Specific Aim 2: Determine the role of pancreatic AT1aRs on β-cell function in
mice with diet-induced obesity.
A. Define the effect of AngII on insulin secretion in isolated islets in obese
mice.
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B. Determine the effect of pancreas-specific AT1aR deficiency on
glycemic control and insulin secretion from islets in obese versus lean
mice.
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Section II. SPECIFIC AIM 1
2.1 Summary
Pancreatic islets express angiotensin-converting enzyme 2 (ACE2), which
catabolizes angiotensin II (AngII) to generate angiotensin-(1-7) (Ang-(1-7)). The
role of ACE2 in β-cell function and glucose homeostasis in type 2 diabetes (T2D)
has not been well-defined. In this study, we determined the effect of ACE2deficiency on the adaptive β-cell hyperinsulinemic response to obesity. Male
mice with a whole-body deficiency of ACE2 (Ace2-/y) and their wild-type littermate
controls (Ace2+/y) were fed a high fat (HF) or control low fat (LF) diet for 4
months. On standard mouse diet, 8 week-old Ace2-/y mice had reduced plasma
insulin compared to wild-type controls resulting in mild hyperglycemia during a
glucose tolerance test.

Plasma insulin remained diminished in Ace2-/y mice

compared to Ace2+/y mice over 4 months of HF-feeding. Moreover, with chronic
HF-feeding, ACE2-deficient mice became obese and developed insulin
resistance to the same degree as wild-type controls, but were not able to
maintain an adaptive increase in insulin secretion. This was associated with
hyperglycemia in the fed, but not fasted state, indicating that deficits in the
adaptive

hyperinsulinemic

response

are

manifest

as

impaired

glucose

homeostasis. Since plasma insulin was reduced in Ace2-/y compared to Ace2+/y
mice as early as 1 month of HF-feeding, early β-cell dysfunction was further
defined at this time point.

1-month HF-fed Ace2-/y mice displayed impaired

glucose-stimulated insulin secretion (GSIS) in vivo compared to Ace2+/y mice
which was associated with increased plasma glucose and no difference in body
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weight or insulin resistance. Since deficiency of ACE2 could influence pancreatic
function either by increasing AngII (and AT1R functions) or by reducing Ang-(17), we defined if initial in vivo deficits in glucose-stimulated insulin secretion
(GSIS) of HF-fed ACE2 deficient mice could be prevented by AT1R blockade or
by infusion of Ang-(1-7). Antagonism of the AT1R improved glucose tolerance in
both genotypes, likely through improvements in insulin sensitivity, however in
vivo deficits in GSIS of HF-fed ACE2 deficient mice could not be overcome by
AT1R blockade or by Ang-(1-7) infusions, suggesting mechanisms that are
unrelated

to

angiotensin

peptide

balancing

properties

of

ACE2.

Immunohistochemical analysis of pancreatic sections revealed that while HFfeeding increased β-cell mass and average islet area in both genotypes, obese
ACE2-deficient mice had significantly less β-cell mass and smaller islet area than
obese wild-type mice. Further, ACE2-deficiency was associated with significantly
reduced proliferation of β-cells in response to HF-feeding. These results suggest
that ACE2 is a critical regulator of β-cell compensatory responses to HF-induced
hyperinsulinemia.
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2.2 Introduction
Drugs that inhibit the renin-angiotensin system (RAS) have been shown to
delay the onset of type 2 diabetes (T2D) (312) (192). Efficacy of RAS blockade
in T2D may relate to improvements in insulin sensitivity or β-cell function during
the adaptive phase of hyperinsulinemia. Several components of the RAS are
present in rodent and human pancreatic islets (55) (166) (271) including the
monocarboxypeptidase angiotensin-converting enzyme 2 (ACE2) that cleaves
angiotensin II (AngII) to generate angiotensin-(1-7) (Ang-1-7) (74).

Local

pancreatic ACE2 may control AngII levels at islets and serve as an endogenous
mechanism to limit RAS activity. Indeed, recent studies suggest that ACE2 is a
positive regulator of pancreatic function (58) (124) as mice with whole body
deficiency of ACE2 became progressively glucose intolerant due to impairments
in insulin secretion (203). Moreover, in mice fed a high fat (HF) diet, whole body
ACE2 deficiency deteriorated islet function through a mechanism involving
impairment

of

islet

microvasculature

(311).

Conversely,

adenoviral

overexpression of ACE2 in the pancreas of db/db mice improved glycemic
control through Ang-(1-7) effects at Mas receptors (28).

Notably, over-

expression of ACE2 in pancreas increased β-cell proliferation and reduced β-cell
apoptosis in 8-week old db/db mice, but had no effect in 16 week old db/db mice
when glycaemia was severely impaired. These findings suggest that ACE2 may
play a role in the adaptive β-cell hyperinsulinemic phase of T2D.
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Previously, we demonstrated that plasma and tissue concentrations of AngII
are increased in glucose intolerant mice with HF diet-induced obesity (39).
Moreover, our previous studies suggested that deficits in ACE2 may contribute to
an increase in the balance of AngII versus Ang-(1-7) in obese mice (122). In this
study, we hypothesized that deficiency of ACE2 impairs the adaptive β-cell
hyperinsulinemic response to HF diet in the progression to T2D.

We first

quantified plasma insulin secretion in wild type and ACE2 deficient mice
chronically fed a low fat (LF) or HF diet.

Since deficiency of ACE2 could

influence pancreatic function either by increasing AngII (and AT1R functions) or
by reducing Ang-(1-7), we defined if initial in vivo deficits in glucose-stimulated
insulin secretion (GSIS) of HF-fed ACE2 deficient mice could be prevented by
AT1R blockade or by Ang-(1-7). Finally, we focused on the regulation of β-cell
mass in HF-fed ACE2 deficient mice as a mechanism for deficits in the adaptive
hyperinsulinemic response.
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2.3

Materials and Methods

2.3.1

Experimental animals and diets.

All studies were conducted according to National Institutes of Health Guide
for the Care and Use of Laboratory Animals and were approved by the University
of Kentucky Institutional Animal Care and Use Committee. Male Ace2+/y and
Ace2-/y littermates on a C57BL/6 background (2 months of age; bred from male
Ace2-/y and female Ace2+/- breeding pairs) were fed either LF (10% kcal as fat;
D12450B; Research Diets, New Brunswick, NJ) or HF diets (60% kcal as fat;
D12492; Research Diets) ad libitum with free access to water for 5 weeks (n=5-6
per group) or 17 weeks (n=5-11 per group). In a separate study, male Ace2+/y
and Ace2-/y mice (2 months of age; n=12-16 per group) were infused via osmotic
minipump (Alzet, model 2006) with losartan (Los; 17 µg/kg/min, Merck,
Whitehouse Station, NJ) (181), Ang-(1-7) (0.4 µg/kg/min, Bachem, Torrence, CA)
(276) or saline (Sal) and fed a HF diet for 28 days.

Plasma Ang-1-7

concentrations were quantified by ELISA using a commercial kit (Peninsula
Laboratories, San Carlos, CA). At study endpoint, mice were anesthetized with
ketamine/xylazine (100/10 mg/kg) for exsanguination and tissue harvest.
2.3.2

Glucose tolerance, insulin tolerance, and plasma glucose/insulin

quantification.
Following a 6 hour fast, blood glucose concentrations were quantified using a
glucometer (Freedom Freestyle Lite, Abbott Laboratories, Abbott Park, IL)
immediately before and 15, 30, 60, 90, and 120 minutes following intraperitoneal
(i.p.) administration of glucose (2 g/kg body weight).
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Insulin tolerance was

assessed following a 4 hour fast by quantifying blood glucose concentrations at
0, 30, 60, and 90 minutes after administration of human insulin (Regular®, 0.5
U/kg body weight, i.p., Novo Nordisk, Princeton, NJ). Both glucose tolerance and
insulin tolerance are expressed as area under the curve (AUC). Plasma insulin
and glucose concentrations were quantified from blood samples (10-15 µl)
collected via tail stick in conscious mice (n=5 mice per group) following a 6 hour
fast and again after i.p. administration of glucose. Plasma insulin concentrations
were quantified by ELISA using a commercial kit (Crystal Chem, Downers Grove,
IL).
2.3.3

Glucose-stimulated

insulin

secretion

(GSIS)

from

isolated

pancreatic islets.
The method for islet isolation was adapted from published protocols (270)
(51). Pancreata were perfused in vivo through the common bile duct with 5 mLs
of collagenase (0.6 mg/mL, Collagenase P, Roche, Indianapolis, IN) immediately
following exsanguination. The excised pancreata were incubated in 10 mLs of
collagenase at 37ºC for 15-20 minutes, and the tissue was then mechanically
separated. Islets were purified from exocrine tissue using a sucrose gradient
(Histopaque 1077, Sigma-Aldrich, St. Louis, MO), allowed to recover in culture
media (RPMI, 10% FBS, 1% penicillin/streptomycin) for 48 hours, and further
purified from exocrine tissue and debris by handpicking with a pipette and
transferring to fresh media. Purified islets (20-25) were placed in inserts in 12
well plates (Greiner Bio One, Monroe, NC) and incubated in Krebs buffer with 3
mM glucose for one hour at 37ºC. The inserts containing the islets were then
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transferred to Krebs buffer with 28 mM glucose and incubated for 1 hour at 37ºC.
Insulin concentrations in media and in islets (harvested in lysis buffer) were
quantified by ELISA and normalized to protein content of islets (BCA assay,
ThermoFisher, Rockford IL).
2.3.4

Determination of pAKT/AKT.

A subset of male Ace2+/y and Ace2-/y mice (n=4-6 per group) infused via
osmotic minipump with losartan, Ang-(1-7) or saline and fed a HF diet for 28 days
were fasted for 4 hours and injected with 10U/kg body weight insulin 15 min prior
to anesthetization and exsanguination. Liver, solei, and subcutaneous adipose
tissue were dissected and frozen in liquid nitrogen. Phosphorylated AKT and
total AKT were assessed using a commercial ELISA kit (Cell Signaling, Danvers,
MA).
2.3.5

Immunohistochemistry and immunofluorescence.

Mouse pancreata were washed in PBS, fixed in 10% formalin overnight at
4°C, dehydrated in grades of ethanol, and paraffin-embedded.

Starting at a

depth of 400 µm, five longitudinal sections (5 µm thick) were prepared every 100
µm.

Sections were deparaffinized, rehydrated in alcohol and subjected to

antigen retrieval (steam; Vector Labs Antigen Retrieval Unmasking Solution).
For β-cell mass and morphometric analysis, sections were incubated with rabbit
anti-insulin antibody (1:100, Abcam ab63820, Cambridge, MA) followed by
incubation with biotinylated anti–rabbit secondary antibody (1:200; Vector Labs,
Burlingame, CA) at 40°C for 30 minutes. A streptavidin-based ABC system and
peroxidase-based red chromagen AEC (both from Vector Labs) were used to
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identify the antigen-antibody reactions, after which sections were counterstained
with hematoxylin. β-cell proliferation was assessed in sections incubated for 20
hours at 4°C with rabbit anti-Ki67 (Abcam ab66155, 1:100) and guinea pig antiinsulin (1:500, Dako A056401-2, Carpinteria, CA) followed by incubation with
goat anti-rabbit Alexa fluor 488 and goat anti-guinea pig Alexa fluor 594 in PBS
for 30 minutes at 40°C then mounted with DAPI. Isotype-matched IgG was used
as controls, as was omission of primary and/or secondary antibodies. Images
were captured with a Nikon Eclipse 80i microscope and analysis was performed
using NIS Elements software (Nikon Instruments, Japan). A commercial kit for
measuring cell death by fluorescein detection of TUNEL staining was used to
measure β-cell apoptosis (Roche, Indianapolis, IN).
2.3.6

Analysis and quantification of β-cell mass, islet size, proliferation,

and apoptosis.
For determination of β-cell mass, an entire pancreas tissue section was
imaged at 4x under brightfield (5 sections per mouse, approximately 120 µm
apart; n=3 mice per group). The total pancreas tissue area and the total insulinpositive (β-cell) area was selected for each image and β-cell mass is reported as
the mean over 5 sections of the ratio of insulin-stained area/total pancreas area
per mouse.

Three 3 mm x 3 mm fields from two sections per animal

approximately 500 µm apart (imaged at 10x) were used to obtain the average
islet area/section (calculated from individual islet areas); data are reported as the
mean islet area per mouse. β-cell proliferation was determined by obtaining the
ratio of area positive for both Ki67 and insulin from individual islets (10-15 islets
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per section imaged at 40x; analyzed from 2 sections per mouse and 3 mice per
group). Apoptosis in β-cells was assessed by counting the number of TUNELpositive cells in sections double-stained for insulin (20 islets per section were
imaged at 20x; 2 sections per mouse and 3 mice per group were used for
analysis).
2.3.7

Statistical analysis.

Data are presented as mean ± SEM. Data were analyzed using two-way
ANOVA with diet and genotype or (treatment where appropriate) as betweengroup factors.

If statistical differences existed between experimental groups,

Holm-Sidac method was utilized for post hoc analyses. Values of P < 0.05 were
considered to be statistically significant. All statistical analyses were performed
using SigmaStat (SPSS).

56

2.4

Results
2.4.1 ACE2-deficient mice fed standard diet have mild impairments in
glucose tolerance and insulin secretion.

ACE2-deficient mice had reduced body weight compared to controls at 8
weeks of age (Figure 2.1A, P<0.01). Insulin tolerance was not different between
genotypes (Figure 2.1B, C). However, during a glucose tolerance test, ACE2deficient mice exhibited increased plasma glucose concentrations at 15 and 30
minutes compared to controls (Figure 2.1D, P<0.05).

Modest elevations in

plasma glucose concentrations did not influence the area under the curve (AUC)
for plasma glucose concentrations (Figure 2.1E).

Notably, plasma insulin

concentrations were significantly lower in Ace2-/y compared to Ace2+/y mice
following a 6 hour fast (time 0, Figure 2.1F; P<0.05) and at 30 minutes postglucose administration (Figure 2.1F, P<0.05).
2.4.2

Plasma insulin concentrations are reduced in hyperglycemic

ACE2-deficient mice chronically fed a HF diet.
We examined effects of chronic (4 month) HF feeding on glucose
homeostasis and the adaptive hyperinsulinemic response in Ace2+/y and Ace2-/y
mice.

Initial body weights of ACE2-deficient mice were lower than controls,

resulting in a modest reduction in body weights of LF-fed ACE2-deficient mice at
study endpoint (Figure 2.2A, P<0.05).

HF-fed mice of each genotype had

significantly increased body weights compared to LF-fed controls, with no
differences between genotypes (Figure 2.2A; P<0.001). Insulin tolerance was
significantly impaired in obese mice of each genotype compared to LF-fed
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controls (Figure 2.2B, C; P<0.01).

Additionally, HF-fed ACE2-deficient mice

became insulin resistant to the same degree as control mice. Fasting plasma
insulin concentrations were significantly reduced in ACE2 deficient mice
compared to controls as early as 1 month of HF feeding, with marked reductions
in plasma insulin concentrations in 4 month HF-fed Ace2-/y mice (Figure 2.2D;
P<0.05).

Although there were no significant differences in fasting plasma

glucose concentrations between HF-fed Ace2+/y and Ace2-/y mice at 4 months
(Figure 2.2E), non-fasted plasma glucose concentrations were significantly
elevated in HF-fed Ace2-/y mice compared to controls (Figure 2.2F, P<0.05).
2.4.3 ACE2-deficient mice have impaired in vivo GSIS after 1 month of
HF-feeding.
Since plasma insulin concentrations were reduced in obese ACE2-deficient
mice compared to controls after 1 month of HF-feeding, we sought to determine if
β-cell dysfunction was also present at 1 month of HF feeding in ACE2-deficient
mice.

Both groups of mice developed hyperinsulinemia, hyperglycemia, and

insulin resistance (Figure 2.3A-D; P<0.01).

However, plasma insulin

concentrations were significantly lower in HF-fed ACE2-deficient mice following a
6 hour fast (time 0, Figure 2.3A; P<0.05) and at 30 and 60 minutes following
intraperitoneal glucose administration compared to Ace2+/y controls (Figure 2.3A,
P<0.05).

Moreover, plasma glucose concentrations were slightly elevated in

ACE2-deficient mice of both genotypes compared to wild-type controls (time 0)
and this effect was significant at 30 minutes following glucose administration
(Figure 2.3B, P<0.05).
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To determine if deficits of in vivo GSIS of ACE2-deficient mice resulted from
impaired insulin secretion from pancreatic islets, we quantified GSIS from
isolated pancreatic islets from mice of each genotype and diet.

Under high

glucose conditions, islets from HF-fed mice of each genotype exhibited
significantly increased GSIS compared to islets from LF-fed mice (Figure 2.3E;
P<0.05). However, there were no significant differences in insulin secretion from
islets of HF-fed mice of either genotype.
2.4.4 Neither infusion of an AT1R antagonist nor infusion of Ang-(1-7)
restore in vivo deficits of GSIS in HF-fed ACE2-deficient mice.
Since ACE2 cleaves AngII to Ang-(1-7), we determined if antagonism of AngII
effects at AT1R (by infusion of Los), or infusion of Ang-(1-7) to restore plasma
peptide concentrations in HF-fed (1 month) ACE2 deficient mice would reverse in
vivo deficits of GSIS. Infusion of Los had no effect on plasma concentrations of
Ang-(1-7) in Ace2+/y or Ace2-/y mice (Fig. 4A). However, infusion of Ang-(1-7)
significantly increased plasma Ang-(1-7) concentrations in both genotypes, with
no differences between genotypes (Figure 2.4A).
Administration of Los significantly improved glucose tolerance compared to
Sal in mice of each genotype, with no differences between genotypes (Figure
2.4B; P<0.05). However, Los administration significantly decreased fasting blood
glucose concentrations in Ace2+/y, but not in Ace2-/y HF-fed mice (Figure 2.4C;
P<0.05).

Moreover, fasting blood glucose concentrations were significantly

increased in Ace2-/y mice regardless of treatment group compared to control
(Figure 2.4C; P<0.05).

As described above (Figure 2.3A), plasma insulin
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concentrations following in vivo glucose administration were significantly lower in
HF-fed Ace2-/y compared to Ace2+/y mice (Sal groups, Figure 2.4D; P<0.05). Los
administration was unable to restore plasma insulin concentrations in HF-fed
Ace2-/y mice to the level of controls (Sal groups, Figure 2.4D).

Since Los

administration improved glucose tolerance, but had no effect on plasma insulin
concentrations in mice of either genotype, we quantified tissue (skeletal muscle,
adipose) concentrations of pAKT as an index of insulin sensitivity.

Los

administration significantly increased the ratio of pAKT to AKT in soleus muscle
and subcutaneous adipose tissue of both genotypes compared to Sal controls,
with no differences between genotypes (Figure 2.4E, F; P<0.05).
Despite significant elevations in plasma Ang-(1-7) concentrations in mice
infused with the peptide (Figure 2.4A), Ang-(1-7) had no effect on glucose
tolerance (Figure 2.4B) or fasting blood glucose concentrations (Figure 2.4C) in
mice of either genotype.

Moreover, infusion of Ang-(1-7) had no effect on

plasma insulin concentrations in Ace2+/y or Ace2-/y HF-fed mice (Figure 2.4D).
2.4.5 HF-fed ACE2-deficient mice have reduced islet size and β-cell
mass.
To define mechanisms for in vivo deficits in GSIS of HF-fed Ace2-/y mice, we
quantified average islet area and β-cell area (mass) in pancreatic sections from 1
month LF- and HF-fed mice of each genotype (representative images in Figure
2.5A).

In LF-fed mice, average islet area and β-cell mass were significantly

decreased in Ace2-/y compared to Ace2+/y mice (Figure 2.5B,C; P<0.05). HFfeeding significantly increased β-cell mass in both genotypes (Figure 2.5A,B;
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P<0.05). However, the magnitude of increase in β-cell mass was greater in
Ace2+/y (44%) compared to Ace2-/y (30%) mice. Moreover, average islet area
and β-cell mass were significantly reduced in HF-fed Ace2-/y compared to Ace2+/y
mice (Figure 2.5B, C; P<0.05).
2.4.6 β-cell proliferation is decreased in HF-fed ACE2-deficient mice.
To define mechanisms for reductions in β-cell mass of HF-fed Ace2-/y mice,
we measured β-cell proliferation by quantifying double-staining of pancreatic
sections from 1 month LF- and HF-fed mice of each genotype for insulin and
Ki67 (respresentative image, Figure 2.5D).

Low proliferation of β-cells was

observed in LF-fed mice, and there were no differences between genotypes. In
HF-fed Ace2+/y mice, β-cell proliferation was significantly increased (3-fold)
compared to LF controls (Figure 2.5E; P<0.001). In contrast, although β-cell
proliferation was slightly increased in HF-fed Ace2-/y mice compared to LF
controls, the effect was not significant.

Notably, β-cell proliferation was

significantly lower in pancreatic sections from HF-fed Ace2-/y compared to Ace2+/y
mice (Figure 2.5E, P<0.01).

To assess whether apoptosis contributed to

decreased β-cell mass of HF-fed Ace2-/y mice, TUNEL staining was performed on
pancreatic sections. Apoptosis was minimal in islets of LF or HF mice of either
genotype and there was no difference in the number of TUNEL-positive islets
between groups (data not shown).
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2.5

Discussion

It has previously been reported that ACE2 deficiency is associated with
altered glucose homeostasis (203) (25) but mechanisms for this effect have not
been extensively investigated.

Our findings provide new insight into the

importance of ACE2 in the adaptive β-cell hyperinsulinemic response to insulin
resistance.

The onset of T2D in humans is characterized by a decrease in

insulin secretion and an inability to maintain hyperinsulinaemia (223).

A

reduction in the acute insulin response to glucose, considered to be an early
indicator of β-cell dysfunction, is associated with the transition from normal to
impaired glucose tolerance in humans and rodents (300) (7).

Our results

demonstrate that HF-fed ACE2-deficient mice became obese and developed
insulin resistance to the same degree as controls but were not able to maintain
adaptive hyperinsulinemia, resulting in hyperglycemia in the fed state. In vivo
GSIS deficits of HF-fed ACE2 deficient mice were not the result of impaired
insulin secretory mechanisms in pancreatic islets. Rather, HF-fed ACE2 deficient
mice exhibited reductions in β-cell mass associated with impaired proliferative
capacity of islets. Finally, in vivo GSIS deficits of HF-fed ACE2 deficient mice
could not be overcome by AT1R blockade or by Ang-(1-7) infusions, suggesting
mechanisms unrelated to angiotensin peptide balancing properties of ACE2.
These results suggest that ACE2 is a critical regulator of β-cell compensatory
responses to HF-induced hyperinsulinemia.
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Previous studies demonstrate ACE2-deficient mice have low insulin gene
expression (25) and age-dependent impaired first-phase insulin secretion when
fed a standard mouse diet (203). Conversely, ACE2 overexpression improved
first-phase insulin secretion in vivo in db/db mice (28). Our results agree with
and extend these findings by demonstrating that modest impairments in in vivo
GSIS in young ACE2-deficient mice contribute to failure to maintain adaptive
hyperinsulinemia in the development of T2D.

AngII has been suggested to

regulate insulin secretion from islet cells of various species with conflicting
reported findings of a stimulatory effect on insulin secretion from human islets
(224), versus reductions in insulin secretion from primary mouse islets (166).
Our results do not support differences in insulin secretory mechanisms from
pancreatic islets of HF-fed ACE2 deficient mice as contributors to the observed
deficits of in vivo GSIS.

Several studies have demonstrated that AngII can

regulate islet blood flow and thereby influence insulin release (50) (151). Thus,
ACE2 deficiency may have impaired in vivo GSIS of HF-fed mice through
AngII/AT1R-mediated reductions in islet blood flow.

Since administration of

losartan to HF-fed ACE2 deficient mice did not reverse deficits of in vivo GSIS, it
is unlikely that elevated systemic or local AngII concentrations in obese mice
(122) contributed to deficits of in vivo GSIS through AngII/AT1R-mediated
regulation of islet blood flow. These findings agree with a recent study in which
administration of an ACE-inhibitor to ACE2-deficient mice did not correct β-cell
defects (25).
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AT1R antagonists have been shown to improve glucose tolerance and
increase insulin secretion (61) (235), suggesting that AngII acting through the
AT1R contributes to the pathogenesis of T2D. Consistent with previous findings
(98), in this study losartan administration improved glucose tolerance in both
genotypes.

Our results suggest that losartan reduces insulin resistance, as

evidenced by increased pAKT/AKT ratios in insulin sensitive tissues. Similarly,
ACE2 activation of the Ang-(1-7)/MasR axis increased insulin secretion in vivo
(28). Specifically, infusion of Ang-(1-7) (at a 4-fold lower dose) improved insulin
sensitivity in non-obese ACE2-deficient mice fed a high sucrose diet (102).
Moreover, in a rat transgenic model of insulin resistance, an oral formulation of
Ang-(1-7) improved insulin sensitivity and glycaemia (241).

Our results

demonstrate that infusion of Ang-(1-7) at a dose that elevated plasma Ang-(1-7)
concentrations and blunted an activated RAS (275) (276) had no effect on
glucose homeostasis in HF-fed mice of either genotype. Differences in the dose
or formulation of Ang-(1-7), coupled with varying models of T2D may have
contributed to diverging effects of the peptide on glucose homeostasis.
Our results demonstrate that the compensatory response to increase βcell mass with chronic HF feeding (71) (133) was blunted in ACE2 deficient mice.
Compensatory β-cell mass expansion is achieved through increases in islet size
(hypertrophy) or β-cell proliferation (hyperplasia) (144). In humans with T2D, a
curvilinear relationship has been reported between β-cell volume and fasting
blood glucose concentrations (230)

Our results agree with previous findings

where islet vascularization and insulin staining were reduced in chronically obese
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ACE2-deficient mice (311). Moreover, our results extend previous findings by
demonstrating insulin deficits at 5 weeks of HF feeding in ACE2-deficient mice
that are associated with decreased β-cell mass and proliferation. Both LF- and
HF-fed ACE2-deficient mice exhibited significant reductions in average islet area
and β-cell mass, which may have contributed to impaired first-phase insulin
secretion and loss of the adaptive hyperinsulinemic response. We found that
reductions in β-cell mass of HF-fed ACE2-deficient mice were attributed to
deficits in proliferation rather than apoptosis, contributing to an impaired adaptive
hyperinsulinemic response to metabolic challenge.
Since neither an AT1R antagonist nor infusion of Ang-(1-7) could restore
deficits in in vivo GSIS of HF-fed ACE2 deficient mice, it is unlikely that
angiotensin peptide balance contributes to effects of ACE2 deficiency. Little is
known about the function of ACE2 independent from its role to enzymatically
cleave AngII in the generation of Ang-(1-7).

ACE2 shares considerable

homology with the membrane protein collectrin, but collectrin lacks an active
dipeptidyl carboxypeptidase catalytic domain.

Both collectrin and ACE2 are

reported to be downstream targets of the transcription factor hepatocyte nuclear
factor-1α (HNF-1α) (101) (211), which is mutated in maturity-onset diabetes of
the young (MODY) (307). Collectrin has been demonstrated to increase insulin
secretion in vitro (13) through regulation of insulin exocytosis (101). However,
mixed results have been reported regarding the role of collectrin to regulate cell
growth of pancreatic β-cells, as overexpression of collectrin increased β-cell
mass in vivo (12) but had no effect on β-cell proliferation in vitro, while whole
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body collectrin deletion had no effect on β-cell mass (188).

Since ACE2

deficiency had no effect on insulin secretion from isolated islets but did regulate
β-cell mass, these results do not support a role for the collectrin domain of ACE2
as the mechanism for impaired adaptive hyperinsulinemia.
In summary, results demonstrate a critical role for ACE2 in the adaptive
hyperinsulinemia response to insulin resistance induced by HF feeding.
Reduced hyperinsulinemia of HF-fed ACE2 deficient mice was detrimental, as
ACE2 deficient mice exhibited hyperglycemia following glucose challenge.
Moreover, insulin deficits did not appear to be related to imbalances in the RAS,
as neither an AT1R antagonist nor infusion of Ang-(1-7) could reverse insulin
deficits of HF-fed ACE2 deficient mice. Rather, ACE2 deficiency reduced the
adaptive response to increase β-cell mass in HF-fed mice, associated with
deficits in β-cell proliferation. These results demonstrate that ACE2 is a critical
regulator of β-cell proliferation and growth, and may serve as a therapeutic target
for T2D.
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Figure 2.1 ACE2-deficient mice fed standard diet exhibit impaired glucose
tolerance associated with reductions of in vivo GSIS. (A) Body weights of 8week old Ace2+/y and Ace2-/y mice (*, P<0.01). (B) Insulin tolerance test and (C)
area under the curve (AUC). (D) Glucose tolerance test and (E) AUC in Ace2+/y
and Ace2-/y mice. #, P<0.05 compared to Ace2+/y within time point. (F) Plasma
insulin concentrations in Ace2+/y and Ace2-/y mice following a 6 hour fast (time =
0) and at 30 minutes after glucose administration.
Ace2+/y within time point.

Data are mean +
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#, P<0.05 compared to

SEM from n=5-11 mice/group.
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Figure 2.2 ACE2-deficient HF-fed mice exhibit diminished adaptive
hyperinsulinemia. Ace2+/y or Ace2-/y mice were fed a HF diet for 17 weeks. (A)
Body weight progression. *, P<0.001 effect of diet and #, P<0.05 effect of
genotype. (B and C) Insulin tolerance test and corresponding AUC. *P<0.01
compared to LF. (D) Fasting plasma insulin concentrations. *, P<0.01 compared
to LF within genotype and #, P<0.05 compared to Ace2+/y within time point. (E)
Fasted plasma glucose and (F) non-fasted plasma glucose in LF and HF-fed
mice. *, P<0.01 compared to LF within genotype and #, P<0.05 compared to
Ace2+/y within diet group. Data are mean + SEM from n=5-11 mice/group.
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Figure 2.3 ACE2-deficient mice have impaired in vivo GSIS after 1 month of
HF-feeding. (A) Plasma insulin concentrations and (B) corresponding plasma
glucose concentrations following acute administration of glucose (2 g/kg body
weight) in LF- and HF-fed Ace2+/y and Ace2-/y mice. *, P<0.01 compared to LF
within time point and #, P<0.05 compared to Ace2+/y within time point. (C) Insulin
tolerance test and (D) corresponding AUC in LF and HF-fed Ace2+/y and Ace2-/y
mice.

*, P<0.01 compared to LF.

(E) Insulin release from pancreatic islets

isolated from LF- and HF-fed Ace2+/y and Ace2-/y mice (n=20 islets per mouse) at
low (3mM) and high (28mM) glucose concentrations. *, P<0.05 compared to LF
within treatment. Data are mean + SEM from n=5-6 mice/group.
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Figure 2.4 Neither AT1R antagonism nor infusion of Ang-(1-7) restore in
vivo deficits in GSIS of HF-fed ACE2-deficient mice. (A) Infusion of Ang-(1-7)
for 1 month increased plasma Ang-(1-7) concentrations in both Ace2+/y and Ace2/y

HF-fed mice compared to mice administered saline (Sal). Infusion of losartan

(Los) had no effect on plasma Ang-(1-7) levels. *, P<0.05 overall effect of Ang(1-7). (B) Glucose tolerance test in 1 month HF-fed Ace2+/y and Ace2-/y mice
administered Sal, Los, or Ang-(1-7). *, P<0.05 overall effect of Los. (C) Fasting
blood glucose concentrations in mice of each genotype and treatment group. *,
P<0.05 overall effect of Los. #, P<0.05 overall effect compared to Ace2+/y. (D)
Plasma insulin concentrations quantified at 60 minutes following glucose
administration. #, P<0.05 overall effect compared to Ace2+/y. (E and F) Ratio of
pAKT to AKT in soleus muscle and subcutaneous (SubQ) adipose tissue,
respectively, from Ace2+/y and Ace2-/y mice infused with Sal, Los, or Ang-(1-7). *,
P<0.05 overall effect of Los. Data are mean + SEM from n=5-8 mice/group.
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Figure 2.5 HF-fed ACE2 deficient mice have reduced β-cell mass and islet
proliferation.

(A) Representative 3mm x 3mm fields from pancreas tissue

sections immunostained with anti-insulin antibody (red) in 1 month LF- and HFfed Ace2+/y and Ace2-/y mice. (B) Average islet area in LF- and HF-fed mice of
each genotype.

#, P<0.01, compared to Ace2+/y within diet group. (C) β-cell

mass as determined by the percent insulin-positive (β-cell) area per total area of
pancreatic sections in LF- and HF-fed mice of each genotype.

*, P<0.05,

compared to LF within genotype; #, P<0.05, compared to Ace2+/y within diet
group.

(D) Representative immunofluorescence images in islets from HF-fed

Ace2+/y and Ace2-/y mice – insulin (red), Ki67 (green) and DAPI staining of nuclei
(blue).

(E) Quantification of the Ki67+/insulin+ ratio showing marked β-cell

proliferation in LF- and HF-fed mice.

*, P<0.001, compared to LF within

genotype; #, P<0.01, compared to Ace2+/y within diet group. Data are mean +
SEM from n=3 mice/group.
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Section III. SPECIFIC AIM 2
3.1

Summary

Diet-induced obesity promotes type 2 diabetes (T2D). Drugs that inhibit the
renin-angiotensin system (RAS) have been demonstrated in clinical trials to
decrease the onset of T2D. Pancreatic islets have been reported to possess
components of the renin-angiotensin system (RAS), including angiotensin type
1a receptors (AT1aR). Previously, we demonstrated that mice made obese from
chronic consumption of a high-fat diet (HF) have marked elevations in systemic
concentrations of angiotensin II (AngII).

We tested the hypothesis that

pancreatic-specific deletion of the AT1aR would improve glucose-stimulated
insulin secretion (GSIS) from isolated islets of mice with diet-induced obesity.
We demonstrated that GSIS from islets isolated from HF, but not low-fat (LF)
mice was markedly diminished in the presence of AngII compared to vehicle
(VEH). Based on these findings, we developed a mouse model of pancreaticAT1aR deficiency.

AT1aRfl/fl mice on a C57BL/6 background were bred to

transgenic Cre mice expressing the pdx-1 promoter to generate pancreatic
AT1aR-deficient mice (AT1aRpdx) and littermate controls (AT1aRfl/fl).

AT1R

mRNA expression was markedly decreased in whole pancreas, but not other
tissues, in AT1aRpdx mice.

AT1aRpdx mice had reduced pancreatic weight

compared to littermate controls, but there was no difference in body weight.
Further, there was no effect of pancreatic AT1aR deletion to impair glucose
tolerance or GSIS in vivo in AT1aRpdx mice compared to AT1aRfl/fl mice fed a
standard murine diet.

77

Male, 8-week old AT1aRfl/fl and AT1aRpdx mice were fed a HF or LF diet for 16
weeks. There was no effect of pancreatic AT1aR-deficiency on the development
of obesity.

HF-fed mice became glucose intolerant and displayed elevated

plasma levels of insulin with no significant difference between genotypes.
However, there was an effect of pancreatic AT1aR-deficiency to impair GSIS in
vivo. AngII significantly reduced insulin secretion from islets isolated from HF-fed
wild-type mice. However, islets isolated from HF-fed pancreatic AT1aR-deficient
mice did not exhibit significant reductions in AngII-mediated insulin secretion.
Unexpectedly, pancreatic AT1aR-deficiency was associated with reduced GSIS
in vitro and reduced islet insulin content. Taken together, these results suggest
complex effects of pancreatic AT1aR deficiency, with possible developmental
effects to impair pancreas growth but potential protective effects against AngIIinduced β-cell dysfunction with HF-feeding. Future studies will define the relative
role of developmental effects of pancreatic AT1aR deficiency from those
regulating GSIS of pancreatic islets of HF-fed mice.
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3.2

Introduction
According to the Centers for Disease Control and Prevention (CDC), 29.1

million adults in the United States (or 9.3% of the population) have diabetes with
new cases diagnosed each year at a rate of 7.8%. Type 2 diabetes (T2D) is
characterized by insulin resistance and the progressive loss of function of
pancreatic β-cells. At the time of diagnosis, the functional capacity of β-cells is
estimated to be about 25% or less (234) and a reduced β-cell function is evident
several years prior to disease onset in individuals with impaired glucose
tolerance (95).

The United Kingdom Prospective Diabetes Study (UKPDS)

demonstrated that declining insulin secretion over time is the main cause of
failure to maintain long-term glycemic control. Further, current medical therapies
for T2D, which substantially lower A1C or fasting plasma glucose compared to
diet alone, were demonstrated to be ineffective against increasing loss of
glycemic control over time (190) (96).
In a 2002 position statement by the American Diabetes Association (ADA),
it was noted that epidemiological studies indicate a continuous association
between the risk of cardiovascular complications and glycemia, as well as
between systolic blood pressure and complications of diabetes such as stroke,
diabetes-related deaths, heart failure, microvascular complications, and visual
loss. Drugs that inhibit the renin-angiotensin system (RAS) have been used
traditionally to treat hypertension and have been shown in clinical trials to
improve cardiovascular outcomes beyond that of blood pressure control in both
diabetic and non-diabetic patients (313) (76) (97).
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In addition to improved

cardiovascular protection, results from several clinical trials suggest that
pharmacologic inhibition of the RAS may protect against the development of T2D
(312) (192) (202) (20).
Inhibition of the RAS has been shown in animal models of T2D to improve
insulin sensitivity and β-cell function (61) (235).

Pancreatic β-cells express

several components of the RAS, including the angiotensin type 1 receptor
(AT1R), (55) (49) (166).

Infusion of angiotensin II (AngII) to mice has been

reported to promote hyperglycemia and reduce glucose-stimulated insulin
secretion (GSIS) from isolated islets (58) (246). Conversely, administration of an
AT1R antagonist to db/db or obese mice improved β-cell function and glycemic
control (61) (68) (98). In humans, several clinical trials have demonstrated an
effect of RAS blockade to reduce the risk of new-onset diabetes (NOD), although
conflicting results have been reported. In the Diabetes Reduction Assessment
(DREAM) study, which excluded patients with significant cardiovascular risk, the
ACE inhibitor ramipril was shown to have no significant effect versus placebo on
the incidence of NOD and only a moderate improvement in glycemia after three
years of follow-up (37).

The Nateglinide and Valsartan in Impaired Glucose

Tolerance Outcomes Research (NAVIGATOR) study demonstrated 14% risk
reduction in the development of T2D in patients with one or more cardiovascular
risk factor (192). It is possible that the effectiveness of RAS blockade to reduce
new-onset diabetes is seen only in patients with an activated RAS.
We have demonstrated that high-fat (HF) feeding in rodents is associated
with development of obesity-hypertension and activation of the systemic RAS in

80

the form of elevated plasma concentrations of AngII (39) (121) (309). These
results suggest that pancreatic β-cells of obese rodents may experience high
concentrations of AngII acting at AT1R. Notably, AT1R gene expression in islets
is reported to be increased by hyperglycemia (170).

In this study, we

hypothesized that elevated systemic or local AngII with obesity acts at pancreatic
AT1aRs to reduce insulin secretion and contribute to the decline in β-cell function
in obese mice. To test this hypothesis, we first examined effects of AngII on
GSIS in islets from chronic HF-fed mice. Based on results from these studies,
we generated mice with pancreas-specific deficiency of AT1aR and investigated
the effect of AngII on insulin secretion from islets isolated from chronic HF-fed
mice with or without pancreatic-AT1aR deficiency.
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3.3
3.3.1

Materials and Methods
Experimental animals and diets.

All experiments were conducted according to the National Institutes of Health
Guide for the Care and Use of Laboratory Animals and were approved by the
University of Kentucky Institutional Animal Care and Use Committee.

Male

C57BL/6 mice (8 weeks of age; The Jackson Laboratory, Bar Harbor, ME) were
randomly assigned to receive either a low fat (LF, 10% kcal from fat; D12450B;
Research Diets, New Brunswick, NJ) or high fat (HF, 60% kcal from fat;
D12450B; Research Diets, New Brunswick, NJ) diet fed ad libitum for 4 months
(n=10 per group).
To generate mice with pancreas-specific deletion of AT1aR, female mice with
loxP sites flanking exon 3 of the AT1aR gene (AT1aRfl/fl) were bred to male
AT1aRfl/fl hemizygous transgenic mice expressing Cre recombinase under the
control of the pancreas-duodenum homeobox-1 (pdx-1) promoter.

Pdx-1, a

transcription factor expressed throughout the pancreas in early embryogenesis
but primarily restricted to insulin-producing β-cells in the adult pancreas, has
been demonstrated as an effective promotor for use in Cre-mediated deletion of
pancreatic proteins (103).

The resulting offspring were either experimental

animals with pancreatic-AT1aR deletion (AT1aRpdx) or littermate controls
(AT1aRfl/fl). Male mice were maintained on standard murine diet (18% kcal from
fat; Harlan Laboratories, Indianapolis, IN) until 8 weeks of age and then were
randomly assigned to receive either a LF or HF diet fed ad libitum for 4 months
(n=5-13 per group). Body weights were measured weekly. 8-week old male and
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female mice were used for tissue characterization of AT1aRfl/fl and AT1aRpdx
mice (n=9-13 per group). Pancreas, heart, liver, kidney, duodenum, stomach,
spleen, lung, soleus, and perigonadal adipose tissue were dissected, frozen in
liquid nitrogen and stored at -80°C until use.

At study endpoint mice were

anesthetized with ketamine/xylazine (100/10 mg/kg) for exsanguination and
tissue harvest.
3.3.2

Extraction of DNA and RNA, quantification of mRNA abundance

using real-time polymerase chain reaction.
DNA was extracted from pancreas (DNeasy; Qiagen, Alameda, CA) and
cDNA

was

generated

TCTTCAAGACTGCTGATGTC

using
and

the

the

following

forward
reverse

primer:
primers:

5’5’

–

GGTTGAGTTGGTCTCAGAC (generates a 355 bp product between loxP site 1
and exon 3 of AT1aR gene demonstrating the presence of the floxed AT1aR
gene) and 5’ – GCAACTATGTCTGTCACTGG (generates a 423 bp sequence
between loxP sites 1 and 3 demonstrating the deletion of exon 3 of the AT1aR
gene). Total RNA was extracted from tissues using the SV total RNA Isolation
System (Promega; Madison, WI) and from isolated pancreatic islets using TRIzol
Reagent (Life Technologies; Grand Island, NY) followed by RNA Clean-up and
Concentrator from Zymo Research (Irvine, CA) and quantity was assessed
spectrophotometrically.

Reverse transcription was performed using qScript

cDNA Supermix (Quanta Biosciences; Gaithersburg, MD) and real-time PCR was
performed using PerfeCTa SYBR Green FastMix (Quanta Biosciences;
Gaithersburg, MD).

Mouse primers used were as follows: AT1R and AT2R
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primers were obtained from Qiagen (Alameda, CA); angiotensin converting
enzyme 2 (ACE2), forward 5’ – ACGAGATGGGACACATCCA, reverse 5’ –
GAAAATCGGATGGCAGAAGA;

AT1b,

forward

5’

–

ATGGGGAGCAGCCAAGAGGC, reverse 5’ – CAGGGCAAGATTCAGAAGGA;
18S

forward,

5’

–

AGTCGGCATCGTTTATGGTC,

reverse

5’

–

CGAAAGCATTTGCCAAGAAT;. Data are expressed as ∆∆Ct relative to 18S
rRNA.
3.3.3

GSIS from isolated pancreatic islets.

The method for islet isolation was adapted from published protocols (270)
(51). Pancreata were perfused in vivo through the common bile duct with 5 mLs
of collagenase (0.6 mg/mL; Collagenase P; Roche, Indianapolis, IN) immediately
following exsanguination. The excised pancreata were incubated in 10 mLs of
collagenase at 37ºC for 15-20 minutes, and the tissue was then mechanically
separated. Islets were purified from exocrine tissue using a sucrose gradient
(Histopaque 1077; Sigma-Aldrich, St. Louis, MO), allowed to recover in culture
media (RPMI, 10% FBS, 1% penicillin/streptomycin) for 48 hours, and further
purified from exocrine tissue and debris by handpicking with a pipette and
transferring to fresh media. Purified islets (20-25) were placed in inserts in 24
well plates (Greiner Bio One; Monroe, NC) and incubated in Krebs buffer with 3
mM glucose (vehicle), angiotensin II (AngII, 10 nM), or losartan (1µM) for one
hour at 37ºC. The inserts containing the islets were then transferred to Krebs
buffer with 28 mM glucose (vehicle), AngII (10 nM), or AngII plus losartan (1µM)
and incubated for 1 hour at 37ºC. Insulin concentrations in media and in islets
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(harvested in acid-ethanol) were quantified by ELISA using a commercial kit
(Crystal Chem; Downers Grove, IL) and normalized to protein content of islets
(BCA assay; ThermoFisher, Rockford IL) or total initial insulin concentration.
3.3.4

Glucose

tolerance

and

plasma

glucose/insulin/glucagon

quantification.
Following a 6 hour fast, blood glucose concentrations were quantified using a
glucometer (Freedom Freestyle Lite; Abbott Laboratories; Abbott Park, IL)
immediately before and 15, 30, 60, 90, and 120 minutes following intraperitoneal
(i.p.) administration of glucose (1.5 g/kg body weight).

Glucose tolerance is

expressed as either a time course following glucose administration or as area
under the curve (AUC).

Plasma insulin and glucose concentrations were

quantified from blood samples (10µl) collected via tail stick in conscious mice
(n=5 mice per group) following a 6 hour fast and again after i.p. administration of
glucose (2 g/kg body weight). Plasma insulin concentrations were quantified by
ELISA (Crystal Chem; Downers Grove, IL).

Plasma glucagon concentrations

were quantified in non-fasted mice by ELISA (Crystal Chem; Downers Grove, IL).
3.3.5

Statistical analysis.

Data are presented as mean ± SEM. Two-tailed Student’s t-tests were used
for analysis of data between two groups. Data were analyzed using two-way
ANOVA with diet and treatment, diet and genotype, genotype and treatment, or
genotype and time as between-group factors, where appropriate. If statistical
differences existed between experimental groups, Holm-Sidac method was
utilized for post hoc analyses.

Values of P<0.05 were considered to be
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statistically significant. All statistical analyses were performed using SigmaStat
(SPSS).
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3.4

Results
3.4.1 AngII inhibits GSIS from isolated islets of obese, glucose intolerant
mice.

Mice fed a HF diet for 4 months became obese (Figure 3.1A; P<0.001),
displayed elevated plasma concentrations of insulin compared to LF controls
(Figure 3.1B; P<0.05), and developed glucose intolerance (Figure 3.1C, D;
P<0.01).

Pancreatic islets were isolated from LF- and HF-fed mice and

stimulated with glucose to release insulin in the presence or absence of AngII,
with or without losartan. In LF-fed mice, incubation of islets with AngII had no
effect on GSIS (Figure 3.1E; P>0.05). However, in islets isolated from HF-fed
mice, incubation with AngII significantly blunted insulin release compared to
vehicle (Figure 3.1E; P<0.05). Incubation of islets with losartan totally abolished
AngII-induced reductions in GSIS.

Islets from HF-fed mice did not exhibit

significant differences in AT1aR mRNA abundance (Figure 3.1F; P=0.25);
however, ACE2 mRNA abundance was significantly decreased in islets from HFfed mice compared to LF-fed controls (Figure 3.1G; P<0.05).
3.4.2 Development and characterization of a mouse model of pancreasspecific AT1aR deletion.
To test the hypothesis that elevated systemic levels of AngII with HF-feeding
act at pancreatic AT1aR to decrease GSIS and impair glucose homeostasis, we
created a mouse model of pancreas-specific AT1aR deficiency.

The AT1aR

gene was deleted from pancreas using the Cre-LoxP system driven by the
pancreas-specific promoter, pdx-1 (Figure 3.2A). AT1aR deletion was confirmed
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by PCR using DNA samples from whole pancreas (Figure 3.2B).

In whole

pancreas, AT1aR mRNA abundance was significantly decreased in AT1aRpdx
mice compared to AT1aRfl/fl controls (Figure 3.2C; P<0.05). In contrast, AT1R
mRNA gene expression was not significantly different between genotypes in
heart, liver, kidney, duodenum, stomach, spleen, lung, soleus, or adipose tissue
(perigonadal). AT1bR gene expression in pancreas was not significantly different
in AT1aRpdx compared to AT1aRfl/fl mice (Figure 3.2D) and AT2R mRNA was not
detected in either genotype.
In AT1aRfl/fl and AT1aRpdx mice fed standard murine diet, there was no
significant difference in body weight (Figure 3.3A) or tissue weight of heart, liver,
kidney,

duodenum,

stomach,

spleen,

lung,

soleus,

or

adipose

tissue

(perigonadal) (Table 3.1). However, pancreas weight was significantly reduced
in AT1aRpdx mice compared to AT1aRfl/fl mice (Figure 3.3B; P<0.01). Reductions
in pancreas weight did not alter pancreatic function, as there were no significant
differences in glucose tolerance (Figure 3.3C,D), in vivo GSIS (Figure 3.3E), or in
non-fasted plasma insulin concentrations (Figure 3.3F). In addition, non-fasted
plasma glucagon concentrations did not differ between AT1aRfl/fl and AT1aRpdx
mice (0.142 + 0.008 versus 0.167 + 0.011 ng/mL, respectively; P=0.09).
3.4.3 Pancreatic AT1aR deficiency has no effect on whole body glucose
homeostasis in chronic HF-fed mice.
Pancreatic AT1aR deficiency had no significant effect on body weight in LF or
HF-fed mice (Figure 3.4A). Chronic HF feeding resulted in significant impairment
in glucose tolerance as indicated by a significant increase in area under the
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curve (AUC) in both genotypes, with no significant differences between
genotypes (Figure 3.4B).

Plasma insulin concentrations were significantly

increased in HF-fed mice of each genotype, with no significant differences
between genotypes (Figure 3.4C, time 0; P<0.05). At 30 minutes post-glucose
administration, plasma insulin concentrations were not significantly different
between genotypes (Figure 3.4C, time 30; P>0.05).
3.4.4 Despite a lack of effect of pancreatic AT1aR deficiency to regulate
in vivo GSIS, the effect of AngII to decrease in vitro GSIS from pancreatic
islets is abolished in HF-fed mice with pancreatic AT1aR deficiency.
Pancreatic islets from HF-fed mice were isolated and stimulated with glucose
to release insulin in the absence or presence of AngII.

Similar to previous

findings (Figure 3.1E), incubation of islets from HF-fed AT1aRfl/fl mice with AngII
significantly inhibited GSIS, which was prevented by pre-incubation of islets with
losartan (Figure 3.4D; P<0.05). In contrast, islets from HF-fed AT1aRpdx mice
had significantly reduced GSIS in the absence or presence of AngII compared to
AT1aRfl/fl controls (Figure 3.4D; P<0.05). As a result, there was no effect of AngII
to decrease GSIS in islets from HF-fed AT1aRpdx mice. Insulin content of islets
was significantly decreased in HF-fed AT1aRpdx mice compared to AT1aRfl/fl
controls (Figure 3.4E; P<0.01). As with previous findings (Figure 3.1G), HFfeeding was associated with a significant decrease in the islet mRNA abundance
of ACE2 (Figure 3.4F; P<0.05). Notably, deletion of pancreatic AT1aR prevented
HF-fed mediated reductions

in ACE2 gene expression
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(Figure 3.4F).

3.5 Discussion
It has previously been reported that infusion of AngII in mice impairs glucose
tolerance (58) (246), while blockade of the RAS improves whole body glucose
homeostasis in mouse models of T2D (61) (68). However, systemic effects of
AngII on insulin sensitivity versus effects of AngII directly at the pancreas in the
regulation of β-cell function in models of T2D have not been extensively
investigated. Results demonstrate that exposure of islets from HF-fed mice to
AngII inhibited in vitro GSIS. This effect of AngII to decrease GSIS was not
present in LF-fed mice, suggesting that AngII-induced β-cell dysfunction is
augmented with chronic HF-feeding. We report the generation of a novel mouse
model with pancreas-specific AT1aR deficiency. Notably, pancreas weight was
reduced in pancreatic AT1aR deficient mice fed standard murine diet, suggesting
a potential developmental effect of pancreatic AT1aR deficiency.

Upon HF

feeding, in vivo GSIS of pancreatic AT1aR deficient mice was not different from
HF-fed controls.

However, islets from HF-fed AT1aR deficient mice did not

exhibit AngII-induced reductions in GSIS.

Interestingly, HF-fed pancreatic

AT1aR deficient mice exhibited reductions in islet insulin concentration. Taken
together, our results suggest complex effects of pancreatic AT1aR deficiency,
with potential detrimental developmental effects on the pancreas that are
counterbalanced by protective effects to blunt AngII-induced β-cell dysfunction in
HF-fed mice. Future studies will define the relative role of developmental effects
of pancreatic AT1aR deficiency from those regulating GSIS of pancreatic islets of
HF-fed mice.
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AngII has been reported to regulate insulin secretion; however, results have
been inconsistent.

In mouse models of T2D, exposure to AngII has been

reported to have an inhibitory effect on GSIS (61) (246) and blockade or silencing
of the AT1R has been demonstrated to improve insulin secretion (68) (315). In
contrast, AngII has been reported to stimulate insulin release in studies using
chow-fed mice (112) or islets from non-diabetic human subjects (224). These
data suggest potential stimulatory effects of AngII on insulin release under nonpathological conditions, but deleterious effects on β-cell function in conditions
promoting T2D. The onset of T2D in humans is characterized by a decrease in
insulin secretion and an inability to maintain hyperinsulinemia (223). Our results
demonstrate that although HF-feeding resulted in impaired glucose tolerance,
both wild-type and pancreatic AT1aR-deficient mice exhibited markedly
increased plasma concentrations of insulin.

Thus, the adaptive response to

hyperinsulinemia with HF-feeding was maintained in both groups of mice fed a
HF-diet. These data indicate that HF-fed C57BL/6 mice in this study did not
progress to β-cell failure which may have prevented determination of the effects
of pancreatic AT1aR-deficiency on glucose homeostasis in vivo.

This is

supported by a study demonstrating that even after 10 months of HF-feeding,
total insulin secretion is sufficient to compensate for insulin resistance in
C57BL/6 mice (7).
We report the novel and unexpected finding that pancreatic AT1aR deficiency
reduced basal and glucose-stimulated insulin secretion in vitro, insulin content
from isolated islets of HF-fed mice, and pancreas weight in mice fed standard
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murine diet. Reductions in pancreas weight suggest that deletion of AT1aR may
have a developmental effect on the endocrine pancreas. AT1R expression in the
pancreas has been reported to be localized to β-cells, pancreatic vasculature,
and acinar tissue (271) (173). The pdx-1 promoter is expressed during early
stages of murine development throughout the entire pancreas, including both
endocrine and exocrine cells, but expression is later restricted primarily to the
insulin-producing β-cells (103).

Thus, pdx-1 driven Cre-mediated deletion of

AT1aR occurs in all pancreatic cell types.

No AT1R expression has been

reported in non β-cell endocrine cell types and no studies have specifically
examined effects of AngII to regulate hormone release other than insulin from the
endocrine pancreas.

We report no effect of pancreatic AT1aR deletion on

plasma glucagon concentrations, suggesting pancreatic AT1aR deletion does not
affect α-cells; however, potential developmental effects of AT1aR deletion in
exocrine or other islet cell types are unknown.

Pancreatic progenitor cells

express both AT1R and AT2R, where locally generated AngII was found to exert
mitogenic and anti-apoptotic effects in vitro (171). Systemic blockade of AT2R,
but not AT1R, in mice during the second transition in pancreatic development
reduced the β-cell to α-cell ratio in neonate pups and impaired insulin secretory
function and glucose tolerance in vivo (172). It is possible that deficiency of
AT1aR in pancreas indirectly influenced pancreas development through
unopposed AT2 receptor stimulation. However, as agonist effects of AngII at
AT2R would be anticipated to increase, rather than decrease β-cell development,
mechanisms for effects of AT1aR deficiency on pancreas weight, insulin content
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and release are unclear. Future studies should utilize inducible deficiency of
AT1aR from β-cells of adult mice to eliminate developmental effects of pancreatic
AT1aR deficiency.
Pancreatic islets are highly vascularized and contain a functionally unique
vascular network critical for rapid exchange of nutrients and hormones between
the islet and the bloodstream (18). AngII is a potent stimulator of VEGF-induced
angiogenesis (219) (137) (48) and islet endocrine cell-derived VEGF has been
demonstrated to be a principal regulator of islet vascular development (41).
Pancreas-specific deletion of VEGF-A in mice impaired development of islet
capillaries, and although pancreatic-VEGF-A deficiency was not associated with
a reduction in the total islet area of pancreas it was associated with a reduced
pancreas weight (164). It is possible that AngII may play a role in islet endocrine
cell development through modulation of VEGF-mediated development of islet
vasculature. Interestingly, AngII stimulation of AT1R and AT2R have both been
demonstrated to differentially regulate the VEGF driven angiogenic response in
endothelial cells in vitro where AT1R induced and AT2R inhibited pro-angiogenic
activity (48).
ACE2 has been demonstrated to improve β-cell function in animal models of
T2D through increasing the activity of the Ang-(1-7)/Mas receptor axis of the RAS
(28).

Infusion of AngII into mice, resulting in impaired glucose tolerance,

increased AT1R expression and decreased ACE2 expression in pancreas, which
was prevented by pancreas-targeted ACE2 gene therapy (58). These results
demonstrate an inhibitory effect of AngII on ACE2 expression in the pancreas.
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Our results are consistent with these findings in that ACE2 gene expression was
significantly decreased in islets isolated from HF- versus LF-fed mice. Moreover,
pancreatic deletion of AT1aR prevented reductions in ACE2 gene expression in
HF-fed mice. Increased activity of ACE2 may contribute to protective effects of
pancreatic AT1aR deficiency in HF-fed mice.
In summary, results suggest complex effects of pancreatic AT1Rs with a
potential role in pancreatic development, but deleterious effects during dietinduced development of T2D. AngII inhibited insulin release from islets isolated
from HF-fed mice. However, in C57BL/6 HF-fed mice that did not exhibit deficits
in β-cell function, there was no effect of pancreatic deficiency of AT1aR on in vivo
β-cell function. Although pancreatic AT1aR-deficiency prevented AngII-mediated
reductions in insulin secretion in vitro, there was an unexpected overall effect of
reduced GSIS and insulin content of islets. Given that pancreas weight was
reduced in pancreatic AT1aR-deficient mice, these results suggest a potential
developmental defect as a result of pancreatic AT1aR deletion. Future studies
will define developmental effects of pancreatic AT1aR deficiency versus those
regulating GSIS of pancreatic islets of HF-fed mice and will focus on the effects
of pancreatic AT1aR deletion to improve β-cell function in mice displaying a more
pronounced β-cell failure phenotype.
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Table 3.1 Tissue weights of AT1aRfl/fl and AT1aRpdx mice fed a standard murine
diet.
AT1aRfl/fl
Male
Female
0.16 + 0.01
0.14 + 0.01

AT1aRpdx
Male
Female
0.15 + 0.01 0.13 + 0.01

Liver

1.33 + 0.06

1.06 + 0.07

1.31 + 0.12

1.22 + 0.03

Kidney

0.39 + 0.02

0.3 + 0.02

0.36 + 0.02

0.31 + 0.01

Duodenum

0.11 + 0.01

0.10 + 0.01

0.12 + 0.02

0.11 + 0.02

Stomach

0.19 + 0.01

0.19 + 0.01

0.16 + 0.01

0.18 + 0.01

Spleen

0.10 + 0.01

0.10 + 0.01

0.09 + 0.01

0.09 + 0.01

Lung

0.18 + 0.02

0.20 + 0.03

0.19 + 0.01

0.18 + 0.03

0.02 + 0.01

0.02 + 0.01

0.02 + 0.01

0.02 + 0.01

0.46 + 0.05

0.43 + 0.14

0.38 + 0.02

0.34 + 0.07

Tissue Weight
(g)
Heart

Soleus
muscle
Adipose
(perigonadal)

Data are mean + SEM from 9-13 per genotype
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Figure 3.1

AngII inhibits GSIS from islets isolated from obese mice.

(A) Body weights of mice fed a LF or HF diet for 4 months. (B) Non-fasted
plasma insulin concentrations are increased in HF compared to LF-fed mice. (C)
Glucose tolerance test and (D) corresponding area under the curve (AUC)
indicating that HF-fed mice become glucose tolerant.
isolated from LF- and HF-fed mice.

(E) GSIS from islets

Treatment of isolated islets with AngII

blunted GSIS in HF-fed mice and the effect could be prevented by pretreatment
with losartan. Data are represented as percent of initial total islet insulin content.
(F and G) AT1R and ACE2 mRNA expression, respectively, in isolated
pancreatic islets. Data are mean + SEM from n=10 mice per group. *, P<0.01,
compared to LF; #, P<0.05 effect of AngII compared to vehicle.
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Figure 3.2 Development and characterization of a mouse model of
pancreas-specific AT1aR deletion. (A) Mice with loxP sites flanking exon 3 of
the AT1aR gene (a) were bred to mice expressing flippase (FLP) which
recognizes the FRT sites to remove the neocassette (b) AT1aRfl/fl mice were bred
to transgenic mice expressing Cre recombinase driven by the pdx-1 promoter to
generate AT1aR deficient mice (AT1aRpdx) and non-transgenic littermate controls
(AT1aRfl/fl) (c). (B) PCR reactions were performed with DNA samples extracted
from pancreas. Primers were designed to detect the deleted portion of exon 3 of
the AT1aR gene. Exon 3 was deleted as demonstrated by the presence of a 432
base pair product. (C) Tissue characterization of AT1R mRNA gene expression
demonstrating AT1R deletion is specific to pancreas.

(D) AT1b mRNA

expression is not different between AT1aRfl/fl and AT1aRpdx mice. Data are mean
+ SEM from n= 9-13 mice per group. *, P<0.05 versus control.
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Figure 3.3 8-week old pancreatic AT1aR-deficient mice fed a standard diet
exhibit normal glycemia. (A) Body weight and (B) pancreas weight of 8-week
old AT1aRfl/fl and AT1aRpdx mice. (C) Glucose tolerance and (D) corresponding
AUC indicating no difference in glucose tolerance between AT1aRfl/fl and
AT1aRpdx mice. (E) Plasma insulin following a 6 hour fast (0 minute time point)
and 30 min following an intraperitoneal glucose challenge.

Both genotypes

respond to glucose with an increase in plasma insulin but there is no different
between genotypes. (F) Non-fasted plasma insulin. Data are mean + SEM from
n=9-12 mice per group. *, P<0.05 compared to AT1aRfl/fl ; #, P<0.01 compared
to 0 minute time point.
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Figure 3.4 AngII-induced reductions in insulin secretion from islets are
prevented in mice with pancreatic-deletion of AT1aR, however this is not
manifest as improved glucose homeostasis
(A) Body weight progression in LF-and HF-fed AT1aRfl/fl and AT1aRpdx mice. (B)
GSIS from islets isolated from obese AT1aRfl/fl and AT1aRpdx mice.

Insulin

secretion is normalized to total protein content. AngII has no effect on insulin
secretion from islets isolated from HF-fed AT1aRpdx mice, whereas insulin
secretion is significantly reduced with AngII treatment in wild-type mice. There is
an overall effect of genotype to reduce insulin secretion in AT1aRpdx mice. (C)
Glucose tolerance represented as AUC. (D) Plasma insulin following a 6 hour
fast and 30 min following an intraperitoneal glucose challenge

Although

pancreatic AT1aR-deficiency prevented AngII-mediated reductions in insulin
secretion in vitro, this did not translate to reduced insulin levels in vivo (either
fasting or post-glucose challenge). Importantly, both groups of mice fed the HFdiet display marked hyperinsulinemia, indicating a lack of progression to β-cell
failure. Data are mean + SEM for n=3-4 mice per group for LF and n= 7-11 mice
per group for HF. *, P<0.01 overall effect of diet; *, P<0.05 effect of AngII
compared to vehicle; #, P<0.05 overall effect of genotype.
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Section IV. GENERAL DISCUSSION
4.1

Summary

The purpose of the studies described in this dissertation was to test the
hypothesis that the RAS contributes to the decline of β-cell function in T2D. We
examined the role of two opposing proteins, ACE2 and AT1aR, in the regulation
of β-cell function and glucose stimulated insulin secretion (GSIS) in vitro and in
vivo.

Specifically, we hypothesized that deficiency of ACE2, which would

increase the balance of angiotensin II (AngII) to angiotensin-(1-7 (Ang-(1-7)),
contributes to the decline in β-cell function with T2D.

Conversely, we

hypothesized that in mice with HF diet-induced obesity, elevated systemic or
local concentrations of AngII act at pancreatic AT1Rs to inhibit insulin secretion.
Whole-body ACE2 deficiency was associated with a reduction in the adaptive
hyperinsulinemic response to chronic obesity, which was manifest as
hyperglycemia in the fed state. β-cell dysfunction was evident as early as 1
month of HF-feeding, as HF-fed ACE2-deficient mice had impaired plasma GSIS.
Reductions in plasma insulin secretion in vivo were not a result of a secretory
defect, but rather due to reduced β-cell mass associated with impaired
proliferative capacity of islets. Notably, reduced β-cell mass was evident in both
LF- and HF-fed mice with ACE2-deficiency. Finally, neither AT1R blockade nor
administration of Ang-(1-7) could restore deficits in in vivo GSIS in HF-fed ACE2deficient mice. These results demonstrate that ACE2 regulates β-cell mass and
is a critical regulator in the β-cell compensatory response to HF-diet induced
insulin resistance (Figure 4.1).
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The contribution of AngII acting at pancreatic AT1aRs to regulate β-cell
function with T2D was also studied. In pancreatic islets isolated from HF-fed
mice, incubation with AngII markedly diminished GSIS and this could be
prevented by pre-treatment with losartan.

Based on these findings, a novel

mouse model of pancreas-specific deletion in AT1aR was developed to
investigate the role of pancreatic AT1R to regulate insulin secretion in mice with
diet-induced obesity.

Upon HF-feeding, there was no effect of pancreatic

AT1aR-deficiency to increase in vivo GSIS or improve glucose tolerance.
However, islets from HF-fed mice deficient in pancreatic AT1R did not exhibit
AngII-mediated reductions in insulin secretion (Figure 4.2).

Interestingly,

pancreatic AT1aR deficiency was associated with reduced GSIS in vitro and
reduced islet insulin content.

Notably, pancreas weight was reduced in

pancreatic AT1aR-deficient mice fed standard murine diet.

Taken together,

these results suggest complex effects of pancreatic AT1aR deletion, with
potential deleterious effects on pancreatic development that are counterbalanced
by protective effects against AngII-mediated β-cell dysfunction with HF-feeding.
Overall, the results of these studies suggest complex roles of ACE2 and
AT1aR to regulate β-cell function both during normal pancreas development and
in response to chronic obesity. Loss of ACE2 may have potential developmental
effects to decrease β-cell mass that are not severe enough to impact glucose
homeostasis under normal conditions.

However, in the face of a metabolic

challenge like obesity, the reduced adaptive capacity of β-cells becomes
manifest as hyperglycemia. While loss of ACE2 seems to exert a deleterious
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effect during development and also reduces β-cell function of adult obese mice,
loss of AT1aR may have differential effects on developing versus adult β-cell
function. Reductions in pancreas weight, insulin secretion, and insulin content
with pancreatic-AT1aR deficiency suggest a role for AngII/AT1aR in normal
pancreas development. However, an ability of AngII to reduce insulin secretion
in islets from HF-fed (but not LF-fed) mice suggest detrimental effects of
AngII/AT1aR on β-cell function during the development of T2D.
4.2

Mechanisms of RAS-mediated impairment in β-cell function

Traditionally, studies of the role of the RAS to regulate β-cell function have
focused on effects of AngII mediated by the AT1R that may contribute to a
decline in β-cell function with T2D. Purported mechanisms of AngII-mediated βdysfunction include reduced insulin secretion due to impaired islet blood flow,
increased inflammation and fibrosis, increased oxidative stress, and increased
apoptosis. Recently, focus has broadened to include favorable effects conferred
by the opposing protein, ACE2. Interestingly, beneficial effects of ACE2 are not
always attributed to the mere counterbalance of the deleterious effects of AngII.
The following sections highlight findings from our studies in relation to previously
reported effects of AngII or ACE2 on the regulation of pancreatic function.
4.2.1 Effects on islet blood flow
Previous studies suggest reductions in insulin secretion may be mediated by
reduced islet blood flow due to vasoconstrictor properties of AngII on the
microvasculature in the pancreas (50). We have demonstrated that chronic HF
feeding in mice is associated with elevated plasma concentrations of AngII that
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contribute to the development of obesity-hypertension (122).

Whether

improvements in glucose tolerance associated with systemic pharmacologic
inhibition of the RAS are due to suppression of an over-active pancreatic RAS
versus improved pancreatic blood flow due to blockade of systemic
vasoconstrictor properties of AngII has been debated.

Recent results

demonstrated that blood pressure normalization in AngII-infused HF-fed mice did
not restore AngII-induced deficits in β-cell function, demonstrating that AngII
directly regulates β-cell function independent of its vasoconstrictor properties
(246). Our data agrees with these findings in that incubation of islets with AngII
ex vivo directly reduced GSIS.
A contribution of ACE2 to regulate β-cell function by influencing islet blood
flow has not been well studied. In mice infused with AngII, overexpression of
ACE2 in the pancreas did not improve islet blood flow but did improve glucose
tolerance (58), suggesting that improved blood flow is not part of the mechanism
by which ACE2 improves glucose homeostasis. In contrast, deficiency of ACE2
may negatively impact islet vascularization.

VEGF expression and islet

vascularization were reported to be reduced in obese ACE2-deficient mice with
impaired plasma GSIS (311). The authors concluded that reduced islet function
in ACE2-deficient mice was due to reduced compensation of islet vascularization
with long-term HF-feeding. Given that AngII is an established positive regulator
of VEGF-driven angiogenesis (219) (137) (48), the finding that islet VEGF
expression and vascularization are reduced in mice with ACE2 deficiency (with
presumed elevations in AngII) is counter-intuitive. Our results demonstrate that
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short-term HF-feeding (1 month) impairs β-cell mass and islet proliferation in
ACE2-deficient mice, but we did not define whether impaired islet vascularization
may have contributed to reductions in β-cell proliferation.

Alternatively,

previously observed reductions in vascularization of islets in ACE2 deficient mice
may be a reflection of reduced β-cell mass, as demonstrated in this study.
Notably, neither administration of an AT1R antagonist or infusion of Ang-(1-7)
reversed the effects of ACE2 deficiency to impair GSIS in vivo. As systemic
delivery of these agents would be anticipated to influence their ability to regulate
islet blood flow, these results also suggest that regulation of islet blood flow is not
the primary mechanism for ACE2-mediated regulation of β-cell mass.
4.2.2 Effects on oxidative stress and inflammation
The deleterious effects of AngII to promote β-cell dysfunction may be driven
in part by increased oxidative stress. It is well accepted that AngII-stimulation of
NADPH contributes to increased production of superoxide and contributes to the
pathology of cardiovascular diseases (107). AngII has been demonstrated to
induce superoxide via NADPH oxidase activation in isolated pancreatic islets
(132) and antagonism of AT1R downregulated components of NADPH oxidase in
β-cells of db/db mice resulting in improved β-cell function (250) (62). In addition
to antagonism of the AT1R, overexpression of ACE2 in the pancreas was also
reported to reduce AngII-mediated increases in oxidative stress (58).
AngII has been recognized as a key mediator of inflammation in a number of
diseases, including chronic kidney disease (237) and vascular diseases (77).
Obesity and T2D are associated with chronic activation of the innate immune
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system (214) and systemic concentrations of proinflammatory cytokines are
positively correlated with progression of T2D (260) (130). Local inflammation of
pancreatic islets has gained recognition as a contributing factor to progressive βcell dysfunction in T2D (86). In human and mouse islets, as well as murine β-cell
lines, exposure to AngII increases mRNA expression of proinflammatory
cytokines (59) (246). Blockade of the RAS in rodent models of obesity reduced
serum and adipose levels of proinflammatory cytokines (68) and reduced gene
expression of inflammatory markers in pancreatic islets (310).

Recently, the

effects of AngII infusion to induce islet inflammation in HF-fed mice were
demonstrated to be mediated by IL-1β, a cytokine previously shown to play a key
role in obesity-associated β-cell dysfunction (246). Reduced plasma GSIS with
AngII infusion was reversed with subcutaneous injection of anti-IL-1β antibodies.
We report no difference in plasma insulin secretion or islet mRNA expression of
IL-1β in HF-fed mice with pancreatic AT1aR deficiency. However, HF-fed mice
of both genotypes in our study displayed marked hyperinsulinemia, suggesting 4
months of HF-feeding in C57BL/6 mice was insufficient to induce progression to
β-cell failure. We anticipate that under experimental conditions promoting β-cell
failure,

pancreatic

AT1aR-deletion

would

diminish

IL-1β-mediated

islet

inflammation.
Effects of ACE2 to counter the negative effects of AngII on islet inflammation
have not been reported; however, one study reported that Ang-(1-7) reduced
expression of inflammatory factors in a pancreatic cell line in vitro (291).
Interestingly, there are other deleterious effects of AngII that are not reported to
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be countered by ACE2. For example, AT1R blockade has been shown to reduce
apoptosis in β-cells (62). However, overexpression of ACE2 in the pancreas of
db/db mice had no effect on apoptosis, but rather increased proliferation of βcells (28). These results are consistent with our finding that ACE2 deficiency
markedly impaired β-cell proliferation but had no effect on apoptosis.

AT1R

antagonism has been demonstrated to improve islet fibrosis in mouse models of
T2D (277) (250). However, neither ACE2 deficiency nor ACE2 overexpression
have been reported to improve fibrosis in β-cells. Taken together, these results
suggest that ACE2 may have beneficial effects on β-cell function that extend
beyond merely reducing the actions of AngII.
4.2.3 Role of the ACE2/Ang-(1-7)/MasR axis
Many of the beneficial effects of ACE2 have been attributed to increased
activity of the Ang-(1-7)/MasR axis. For example, in db/db mice with pancreatic
overexpression of ACE2, improvements in β-cell proliferation were abolished by
administration of a MasR antagonist (28). However, most reported effects of
Ang-(1-7) to improve glucose homeostasis have been ascribed to peripheral
improvements in insulin sensitivity.

Infusion of Ang-(1-7) improved insulin

sensitivity in non-obese mice fed a high-sucrose diet (272) and an oral
formulation of Ang-(1-7) improved glycemia and insulin sensitivity in rodent
models of T2D (241) (241) (207). Our results demonstrate that in obese ACE2deficient mice, infusion of Ang-(1-7) at a dose that elevated plasma Ang-(1-7)
concentrations and reportedly blunted an activated RAS (275) (276) had no
effect on glucose homeostasis and did not correct deficits in plasma GSIS.
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Differences in the dose or formulation of Ang-(1-7), coupled with varying models
of T2D may have contributed to diverging effects of the peptide on glucose
homeostasis.
4.3

Other substrates of ACE2
4.3.1 Dynorphin

In addition to AngII, ACE2 is capable of hydrolyzing the peptide dynorphin-(113) with high catalytic efficiency (288). Dynorphins are a class of opioid peptides
primarily expressed within the central nervous system. Dynorphins are thought
to contribute to regulation of the hypothalamo-pituitary axis and may have a role
in energy homeostasis (238). Insulin secretion from isolated rat islets increased
with dynorphin incubation (116), but intravenous administration of dynorphin to
mice had no effect on insulin secretion (6).

No other studies have been

published investigating the role of dynorphins on insulin secretion or β-cell
function.
4.3.2 Apelin
ACE2 is capable of catabolizing the peptide apelin by cleaving the terminal
amino acid, rendering it biologically inactive (288).

ACE2 is the only enzyme

known to regulate apelin metabolism (150). Apelin, the endogenous ligand of the
G-protein coupled APJ receptor, has been shown to regulate cardiac contractility
(269). The APJ receptor has significant homology to the AT1R, although AngII is
not a ligand for the receptor (204).

The effects of apelin are thought to be

cardioprotective and counterbalance pathological effects of AngII. Apelin mutant
mice demonstrated impaired cardiac contractility and hypertrophy, and increased
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vasoconstrictor responses to AngII, which are rescued by both blockade of
AT1aR or treatment with Ang-(1-7) (245). Additionally, apelin upregulates ACE2
expression in vitro and in vivo (245) further supporting a role for apelin to mitigate
actions of AngII.
The APJ receptor is expressed in pancreatic islets (259) and incubation of
isolated mouse islets with apelin inhibited insulin secretion (259) by activating
PI3-kinase-dependent phosphodiesterase 3B with subsequent suppression of
cAMP levels (120). Apelin is expressed by adipocytes and circulating levels of
apelin are increased with obesity (38). Further, insulin was demonstrated to
positively regulate apelin expression in adipocytes (38). This suggests that the
effects of apelin to decrease insulin secretion may serve as a β-cell protective
mechanism under conditions of increased insulin demand. However, the effects
of apelin on insulin secretion may be exacerbated with ACE2-deficiency,
especially in the context of obesity and increasing apelin concentrations.
Further, ACE2 expression is upregulated by apelin, suggesting apelin is subject
to negative feedback regulation, which may be disrupted with ACE2 deficiency.
Thus, increased actions of apelin may contribute to decreased plasma insulin
concentrations in ACE2-deficient mice. Our results demonstrate reduced β-cell
mass in ACE2-deficient mice, suggesting that possible effects of apelin on insulin
secretion are in addition to effects of ACE2 deficiency to impair β-cell
proliferation.

To date, no studies have investigated the role of apelin in the

regulation of β-cell mass.
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4.4

Non-enzymatic roles of ACE2

ACE2 is well known for its role to cleave AngII to generate Ang-(-1-7) and its
primary function is thought to be the regulation of the relative abundance of these
two opposing peptides. Considerably less is known about the non-enzymatic
functions of ACE2, particularly as it pertains to regulation of glucose
homeostasis.

The following sections provide insight into effects of ACE2 that

may contribute to regulation of β-cell function independently of regulation of
peptide balance.
4.4.1 ACE2 and collectrin
ACE2 shares 47.8% sequence homology with the membrane protein
collectrin, or transmembrane protein 27 (TMEM27), in the transmembrane and
cytosolic regions but collectrin lacks a dipeptidyl-peptidase domain (314). Both
ACE2 (211) and collectrin (101) (248) are reported to be downstream targets of
HNF1-α which is mutated in MODY3 (305). Islet gene expression of collectrin is
reported to be increased in obese mouse models of T2D (101) (12).
Overexpression studies demonstrate that collectrin increases insulin release in
vitro (13) and in vivo by regulating exocytosis (101), and mice with whole-body
knockout of collectrin exhibit reduced serum insulin concentrations (188).
Collectrin has been reported to regulate β-cell mass and proliferation, but mixed
results have been reported as overexpression of collectrin increased β-cell mass
in vivo (12), while whole-body collectrin deficiency had no effect on β-cell mass
(188).
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Gene expression of collectrin was reported to be reduced in whole pancreas
of mice with whole-body deficiency of ACE2 (25).

Since the gene encoding

collectrin is located adjacent to, but not overlapping, the gene encoding ACE2 on
the X chromosome (314), reduced expression of collectrin in ACE2-deficient
mice is not likely to be an artifact of ACE2 deletion. It is not known whether
collectrin is regulated by ACE2 or vice versa. However, it must be considered
whether reduced GSIS in vivo with ACE2 deficiency may be a result of either
reduced collectrin expression or mediated by loss of the collectrin domain of the
ACE2 protein. We report that ACE2 deficiency had no effect on ex vivo GSIS of
isolated islets, but rather reduced β-cell mass, suggesting that loss of the
collectrin domain is not the mechanism for impaired adaptive hyperinsulinemia
with ACE2 deficiency.
4.4.2 Binding of ACE2 to β1-integrin
Recent studies demonstrate that by acting as a binding partner, ACE2 can
influence expression and function of other proteins. ACE2 has been shown to
bind β1 integrin in vitro (65) and an interaction of ACE2 with β1 integrin was
reported in the left ventricle of human hearts in heart failure (177). In this study,
an ACE2 activity assay demonstrated that an ACE2/β1 integrin protein complex
isolated by immunoprecipitation was capable of hydrolyzing AngII, but not AngI.
The investigators proposed that the interaction between ACE2 and β1 integrin
was a regulatory mechanism for ACE2 activity and localization. In another study,
ACE2 augmented integrin-mediated cell adhesion and modulated integrin
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signaling in vitro, suggesting that ACE2/integrin interactions may play a
regulatory role in cellular attachment (65).
No studies have investigated whether ACE2 binds β1 integrin in β-cells, but
β1 integrin has been documented to regulate a variety of functions in the
endocrine pancreas, including adhesion and migration of progenitor cell
populations (63) and secretory functions in adults islets (149).

Recently, β1

integrin was demonstrated to be a crucial regulator of pancreatic β-cell expansion
(84). Diaferia et al demonstrated that mice with β-cell specific deletion of β1
integrin displayed defective β-cell expansion during development, resulting in
reduced β-cell mass that persisted into adulthood. Despite significantly reduced
β-cell number, loss of β1 integrin did not affect differentiation or function of βcells. Interestingly, with respect to glucose homeostasis, adult mice with β-cellspecific deficiency of β1-integrin displayed a phenotype similar to that of ACE2deficient mice reported in this dissertation; specifically a reduced plasma insulin
output in response to glucose. These data make it tempting to speculate that the
effects of ACE2 deficiency to reduce β-cell mass and plasma insulin secretion
may be related to a reduction in ACE2/ β1 integrin-mediated regulation of β-cell
mass. In the study by Diaferia et al, ablation of β1 integrin affected expression of
genes that regulate cell cycle progression. Other studies have demonstrated that
deletion of critical cell cycle regulators in β-cells impairs β-cell mass and plasma
insulin

secretion

(reviewed

by
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Heit,

et

al

(127)).

4.4.3 ACE2 association with the neutral amino acid transporter, B°AT1
In addition to binding integrins, ACE2 has also been demonstrated to
associate with the neutral amino acid transporter, B°AT1 (Slc6a19). B°AT1 cotransports neutral amino acids with Na+ across the apical membrane in intestine
and kidney (89).

Mutations in this transporter lead to Hartnup disorder, an

autosomal recessive disorder characterized by neutral aminoaciduria (155) (247).
Both ACE2 and collectrin serve as partner proteins to B°AT1 in the intestine and
kidney proximal tubule, respectively (46).

ACE2 has been shown to be

necessary for B°AT1 expression in luminal intestine (46) and ACE2 null mice
exhibit defective intestinal amino acid transport associated with decreased weight
gain in pups following weaning (254).

Expression of B°AT1 has not been

reported in pancreas or β-cells, and no studies have identified potential
implications of ACE2 association with B°AT1 on glucose homeostasis. However,
since amino acids co-transported with Na+ are capable of stimulating insulin
secretion (200), it is possible that decreased B°AT1 expression with ACE2
deficiency may contribute to reduced insulin secretion in ACE2 deficient mice.
4.5

Study Limitations
4.5.1 Limitations of the model of whole-body deficiency of ACE2
4.5.1.1 Effects of ACE2 deficiency on fetal development

Maternal ACE2 deficiency has been reported to negatively impact both
maternal gestational body weight gain and pup weight (27), so the effect of ACE2
deficiency to impair intestinal amino acid uptake may have a nutritional
consequence on the development of the pancreas in utero. It is well documented
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that intrauterine growth restriction (IUGR) as a consequence of maternal undernutrition or protein restriction results in low birth weight and increases the risk for
impaired glucose homeostasis or T2D in both animals and humans (216). In
particular, because fetal β-cell mass is primarily established during gestation, βcell mass is particularly sensitive to alterations in the intrauterine environment
(40). Fetal malnutrition or IUGR in rodents is associated with reduced β-cell
mass in adult offspring (106) (253) and while β-cell mass may be sufficient to
maintain glycemia under normal conditions, the effects of perinatal malnutrition
may limit adaptive expansion of β-cell mass under conditions of increased
demand later in life (105).

Thus, effects of ACE2 deficiency to reduce the

adaptive response to obesity in adults may be a consequence of inadequate
establishment of β-cell mass in utero as a result of maternal malnutrition.
Alternatively, IUGR affecting fetal development of β-cell mass with ACE2
deficiency could be due to increased placental ischemia due to vasoconstriction,
as increased concentrations of AngII were reported in the placenta of pregnant
ACE2-deficient mice (27).
4.5.1.2 ACE2 and insulin resistance
It has been reported that ACE2 deficiency affects insulin resistance, although
results have been conflicting. In one study, ACE2 deficient mice were reported
to be insulin resistant compared to wild-type controls due to a reduction in GLUT4 in skeletal muscle (102).

In contrast, a recent study reported that ACE2

deficiency shifts energy metabolism towards glucose utilization and this was
associated with increased insulin sensitivity and an increase GLUT4 mRNA
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abundance in skeletal muscle in ACE2 deficient mice compared to wild-type (25).
We report no effect of ACE2 deficiency on insulin resistance and no difference in
pAKT/AKT ratios in insulin-sensitive tissues with HF-feeding.

Such varying

results could be due to differences in the generation or source of ACE2-deficient
mice, differences in diet compositions, and differences in the strain of wild-type
controls. Differences in insulin sensitivity with ACE2 deficiency could impact βcell adaptive responses to obesity. Use of a model of tissue specific deletion of
ACE2 in β-cells would allow for dissemination between potential peripheral
versus β-cell specific effects of ACE2 deficiency to regulate β-cell function.
4.5.2 Limitations of the model of pancreatic-AT1aR deficiency
The model of pancreatic AT1aR deficiency used in these studies was
developed using the Cre/LoxP system where Cre-mediated deletion of exon 3
(the coding region) of the AT1aR gene was driven by the pdx-1 promoter. Pdx-1
is expressed in the vertebrate posterior foregut endoderm in a region destined to
become the antral stomach, pancreas, and rostral duodenum (258) (103). AT1R
receptor expression has been reported in gastric (123) (123) and duodenal (146)
tissues and AngII was shown to impair intestinal absorption of water and ions in
vitro (174). This has implications for possible pdx-1 driven deletion of AT1aR in
the gastrointestinal tract in our mouse model to affect nutrient absorption or fluid
homeostasis. However, AT1aR mRNA abundance was not significantly different
in pancreatic-AT1aR deficient mice compared to controls. Although no further
investigation was made into possible effects of AT1aR deletion in the
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gastrointestinal tract, these data suggest there is no Cre-mediated deletion of the
AT1aR gene in stomach or duodenum.
During the early stages of embryogenesis, pdx-1 is expressed in both
endocrine and exocrine cells of the pancreas, although the primary abundance in
adults is in insulin-producing β-cells (103). Thus, pdx-1 driven Cre-mediated
deletion of AT1aR occurs in all pancreatic cell types. Validation of cell-specific
deletion of AT1aR at the protein level is difficult due to lack of a specific AT1aR
antibody (225) (131).

However, AT1R expression in the pancreas has been

reported to be localized to β-cells, pancreatic vasculature, and acinar tissue (271)
(173) and no AT1R expression has been reported in non β-cell endocrine cell
types.
4.5.3

Limitations of the use of diet-induced obesity (DIO) as a model for

T2D
DIO in C56BL/6 mice is widely used as a model for T2D. In this dissertation,
this model was selected based on previous findings that plasma concentrations
of AngII are elevated in C57BL/6 mice fed a HF diet for 16 weeks (121) which
provide a basis for the central hypothesis that activation of the RAS with HFfeeding contributes to β-cell dysfunction with T2D. While DIO in C56BL/6 mice
has been reported to be a good model for the development of insulin resistance
(266), results from this study indicate that this model is not well-suited for the
study of β-cell failure with T2D. We report month-to-month increases in plasma
glucose levels at up to 4 months of HF-feeding, indicating steady compensation
to insulin resistance.

This is consistent with other reports that decreases in
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insulin secretion contributing to glucose intolerance are not evident in HF-fed
C57BL/6 mice until 10 months of HF-feeding (7). Future studies should consider
using a model better suited for study of β-cell failure, such as db/db mice, which
display evidence of β-cell failure by 3-4 months of age (70).
4.5.4 Limitations of measuring glucose in vivo
Plasma and blood glucose measurements in this dissertation were performed
using the Freedom Freestyle Lite glucometer (Abbott Laboratories). It should be
noted that blood glucose can be rapidly modulated by the SNS (16) and that care
should be taken to ensure blood glucose measurements are taken under
conditions designed to minimize stress to the animal.

In this study, all

measurements were taken by the same investigator in the same procedural
manner to increase accuracy of glucose measurements. Further, accuracy of the
glucometer, as published by Abbott Laboratories, is reported to be + 20%.
4.6

Clinical Significance
4.6.1 Inhibition of the RAS as a treatment for T2D

Causes of T2D vary widely from monogenic to polygenic forms of T2D and
the risk for development of T2D is complicated by environmental factors, like
obesity, and concomitant health conditions, like cardiovascular disease. Current
therapeutics for T2D are focused on the management of glycemia, and treatment
is based on where an individual lies on the continuum of T2D, rather than the
pathology of individual patients.

Clinical trials have demonstrated that RAS

blockade reduced the risk of new onset diabetes in patients with one or more
cardiovascular risk factors (312) (178) (287) (202) (20).
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Results from meta-

analyses suggest that treatment with an ARB or ACE inhibitor reduces the
incidence of T2D by 16-30% (141) (4) (279). However, in most of the trials
where risk for developing T2D was reduced with RAS blockade, T2D was not a
major endpoint.
Results from the two large prospective studies specifically designed to
investigate the effect of RAS inhibition on the development of T2D were less
favorable than anticipated. In the DREAM trial, 3 years of ramipril treatment
reduced the incidence of T2D by 9%, but the finding was not significant (37); the
incidence of T2D was significantly reduced by rosiglitazone (109).

However,

regression from IGT to normoglycemia was increased in patients given ramipril
versus placebo (37), suggesting a positive effect of RAS inhibition to control
glycemia.

Notably, the patient population in the DREAM trial was free from

cardiovascular diseases. In the NAVIGATOR trial, valsartan and concomitant
lifestyle modification reduced the incidence of T2D by 14% versus lifestyle
modification alone, and patients exhibited reduced fasting and post-load glucose
following an oral glucose test (192).

Although findings from meta-analyses

suggest blockade of the RAS is favorable for reducing the incidence of T2D,
findings vary depending on the patient population, study endpoint, pharmacologic
agent, and duration of study. Such distinctions may be important for identifying
patient populations most likely to benefit from pharmacologic inhibition of the
RAS to improve diabetes outcomes.
In the majority of clinical trials indicating an effectiveness of RAS blockade to
reduce the risk for T2D, the patient population displayed some form of CVD. The
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RAS is upregulated in many cardiovascular pathologies including hypertension
(39), cardiac hypertrophy (11), and heart failure (283) and clinical trials
demonstrate that blockade of the RAS improves cardiovascular outcomes (67)
(21).

Incubation of human islets in high glucose conditions increased gene

expression of RAS components (183) (185) and treatment with ARBs or ACE
inhibitors has been demonstrated to improve β-cell function in humans patients
with hypertension (215) (267) (285).

Further, obesity is associated with an

activation of the systemic RAS (221), and most patients with T2D are obese.
Taken together, these results suggest that the beneficial effects of RAS inhibition
to reduce the incidence of T2D may be most effective in patient populations most
likely to have an increased systemic RAS.
Since T2D is a multi-organ disease, effects of systemic RAS blockade may
have multiple effects beyond direct action at β-cells that ultimately contribute to
improved β-cell function. RAS inhibitors have been demonstrated to improve
insulin resistance in animals and humans (141) (220) (285) and some ARBs,
such as telmisartan, may provide additional insulin sensitizing effects by
agonizing PPAR-γ (176). Improvements in insulin sensitivity may improve β-cell
function by reducing the demand for insulin and thereby protecting against β-cell
exhaustion.

Both ACE inhibitors and ARBs have been demonstrated to have

systemic anti-inflammatory effects (176), which may serve to reduce the
exposure of β-cells to the harmful milieu that can potentiate β-cell dysfunction.
RAS inhibition as a therapeutic option is attractive due to the beneficial effects
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systemically, at peripheral tissues and β-cells, and because of effectiveness to
mitigate dangerous co-existing cardiovascular diseases.
4.6.2 ACE2 as a novel therapeutic treatment
In addition to pharmacologic inhibition of the RAS, studies in animal models of
T2D demonstrate that ACE2, the physiological negative regulator of the RAS,
may be a therapeutic target for treatment of T2D.

Interestingly, ACE2 is

downstream target of HNF1-α (211), and mutations in this transcription factor are
responsible for the most frequent monogenic form of diabetes, MODY3 (99).
MODY3, a distinct subtype of T2D, is characterized by progressive β-cell
dysfunction requiring insulin treatment with onset occurring by about 25-35 years
of age (195). Lehto et al demonstrated that individuals with MODY3 exhibited
decreased fasting and incremental plasma insulin concentrations compared to
individuals with non-insulin-dependent T2D. Compared to individuals with noninsulin-dependent T2D, a key characteristic of MODY3 is the lack of an insulin
resistance phenotype, and importantly, low insulin responses to glucose in
patients with MODY3 were not a function of increased insulin sensitivity.
Mouse models with mutated HNF1-α in β-cells exhibit hyperglycemia,
reduced β-cell mass and proliferation rate, and reduced insulin response to
glucose (306). This phenotype is similar to that observed in our studies where
ACE2 deficient mice displayed hyperglycemia and reduced β-cell mass and
proliferation compared to wild-type controls.

ACE2 overexpression in the

pancreas of db/db mice improved glycemia, β-cell mass and proliferation (28).
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Taken together, these data specifically suggest a role for ACE2 as a therapeutic
target in individuals with MODY3.
4.7

Future Directions
4.7.1 Exploration of ACE2 as a downstream target of HNF-1α

The exact role of ACE2 in the regulation of glucose homeostasis has yet to be
elucidated and there are many possible options for mechanisms by which ACE2
contributes to the regulation of β-cell mass. One area that has yet to be fully
investigated is the relative roles of the catalytic versus collectrin-homologous
domain of ACE2. ACE2 expression or activity has not been characterized in
human patients with MODY3 or animal models with mutations of HNF1-α.
However, decreased expression of collectrin has been documented in mice with
HNF1-α-deficiency (101). Deletion of collectrin in mice impairs insulin secretion,
but does not impair β-cell mass (188), suggesting effects of ACE2 in the
regulation of β-cell function extend beyond effects conferred by the collectrin
domain.

The potential dual function of ACE2 to regulate β-cell mass and

proliferation as well as to increase insulin secretion as a function of the collectrin
domain makes ACE2 activation an attractive therapeutic target for patients with
MODY3 or other forms of T2D characterized primarily by defects in β-cell
function.
4.7.2 Implications of an ACE2/β1-integrin association in the regulation of
β-cell mass
HF-fed ACE2 deficient mice exhibit impaired GSIS as a result of reduced βcell mass due and impaired β-cell proliferation; however, mechanisms by which
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ACE2 regulates cell proliferation are unknown. In adult mice, antagonism of the
AT1R or infusion of Ang-(1-7) in ACE2 deficient mice to restore the peptide
balance did not restore plasma GSIS, suggesting mechanisms unrelated to the
enzymatic function of ACE2. No studies have reported direct effects of ACE2 in
the regulation of the cell cycle. However, ACE2 has been reported to bind with
β1-integrin and influence integrin signaling (65) and β1-integrin has been
demonstrated to regulate β-cell mass possibly through signaling cascades
regulating cell cycle proteins (84). These data suggest a novel role for ACE2 in
the regulation of β-cell proliferation mediated by protein-protein interactions with
β1-integrin.

Future studies would demonstrate co-localization between ACE2

and β1-integrin in β-cells and investigate the role of an ACE2/β1-integrin
association in the regulation of cell cycle proteins and β-cell proliferation.
4.7.3 Developmental versus post-natal roles of ACE2 to regulate β-cell
function
Evidence suggests an effect of ACE2 deficiency to impair β-cell development,
confounding the role of ACE2 in the adaptive β-cell response to obesity in adults.
Future directions include disseminating the relative roles of ACE2 in the
development of β-cell mass versus post-natal regulation of β-cell mass. This
includes not only discerning between maternal effects of ACE2 deficiency to alter
the intrauterine environment versus the role of ACE2 to regulate β-cell mass
during fetal embryonic development, but determining if effects of ACE2 are
related to angiotensin peptide balance versus other, non-enzymatic roles of
ACE2. Our results suggest a role for ACE2 in the post-natal, adaptive β-cell
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response to obesity. Future studies would be best carried out using an inducible
Cre-driven β-cell-specific mouse model.
4.7.4 Use of conditional models of cell-specific AT1aR deletion
We report reduced pancreatic weight and reduced insulin content and GSIS
in vitro in mice with pancreatic AT1aR deficiency, suggesting protective effects of
AT1aR during development of T2D may be masked by a potential developmental
effect. A mouse model where Cre-mediated deletion of AT1aR could be induced
in adulthood would be more effective to define specific effects of AT1aR deletion
to protect against the detrimental effects of AngII during HF-diet-induced T2D. A
variety of mouse models conferring conditional inactivation of genes in various
cell types of pancreas exist and were extensively described in a recent review
(187)
4.7.5 Potentiation of β-cell failure to determine effects of pancreaticAT1aR deletion to protect against AngII-mediated β-cell dysfunction
HF-fed C57BL/6 mice are commonly used as a mouse model for T2D due to
the rapid development of profound insulin resistance accompanied by
hyperinsulinemia (302). However, in an in vivo study, the effects of short-term
versus long-term HF-feeding demonstrated that over three months, impaired
glucose effectiveness was the primary contributor to IGT in C57BL/6 mice.
Decreased acute insulin secretion was observed after 10 months of HF-feeding
in this strain, although total insulin secretion was still sufficient to compensate for
insulin resistance (7). We report marked hyperinsulinemia in pancreatic-AT1aRdeficient mice after 4 months of HF-feeding, indicating a lack of progression to β126

cell failure. Since we did not observe β-cell failure in chronic HF-fed C57BL/6
mice, this most likely precluded an ability to detect a significant effect of
pancreatic AT1aR deficiency on glucose homeostasis. In a recent study, infusion
of AngII via osmotic pump for 28 days to 12-week HF-fed C57BL/6 mice
decreased GSIS in vivo (246). We plan to follow a similar study design using our
mouse model of pancreatic AT1aR-deficiency. We anticipate that infusion of
AngII will augment detrimental effects of HF-feeding on β-cell function and
hypothesize that AngII-infused mice with pancreatic AT1aR-deficiency will have
improved insulin secretion and glucose tolerance in vivo.
4.8

Concluding remarks

Overall these studies demonstrate a protective role for ACE2 in the adaptive
β-cell response to hyperinsulinemia and a detrimental effect of AngII/AT1R on βcell function during the development of diet-induced T2D.

ACE2-deficiency

reduced the adaptive response to increase β-cell mass in HF-fed mice, which did
not appear to be a result of imbalances in the RAS. These data suggest a critical
role for ACE2 to regulate β-cell proliferation and growth and that ACE2 activation
may be a novel therapeutic option to improve β-cell function. Pancreatic-deletion
of AT1aR prevented AngII-mediated decreases in insulin secretion, but may be
associated with potential developmental defects in pancreatic development.
Future studies should define the developmental versus post-natal effects in cellspecific

models

of

β-cell

failure

of

127

ACE2

and

AT1aR

deletion.

Figure 4.1 ACE2 plays a role in β-cell adaptation in response to obesity.
ACE2 deficient mice fed a HF diet have reduced hyperinsulinemia and impaired
in vivo GSIS.

In adult mice, insulin deficits cannot be corrected by AT1R

antagonism or infusion of Ang-(1-7) to restore the peptide balance in ACE2
deficient mice.

Rather, ACE2 deficiency reduced the adaptive response to

increase β-cell mass associated with deficits in β-cell proliferation. These results
demonstrate that ACE2 is a critical regulator of β-cell proliferation and growth.
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Figure

4.2

Pancreatic-AT1aR

deficiency

prevents

AngII-mediated

reductions in insulin secretion ex vivo in islets from HF-fed mice but has
no effect on glucose tolerance in vivo. Deletion of AT1aR from pancreas
prevents AngII-mediated reductions in GSIS from islets isolated from HF-fed
mice. However, pancreatic AT1aR deficiency is associated with reduced GSIS
and reduced insulin content from isolated islets, which may be due to a
detrimental effect of AT1aR deletion on normal pancreas development. Taken
together, these results suggest complex effects of pancreatic AT1aR deficiency,
with potential detrimental developmental effects on the pancreas that are
counterbalanced by protective effects to blunt AngII-induced β-cell dysfunction in
HF-fed mice. These offsetting factors may contribute to the lack of observed
effect of pancreatic AT1aR deletion on glucose homeostasis in vivo.
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